Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Endocytosis (mmu04144)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
1110012M
11Rik
KLA  ATP  ATP+KLA
 NM_028617 RIKEN cDNA 1110012M11 gene (1110012M11Rik), mRNA [NM_028617] KLA .99 1.04 .88 1.21 1.12 1.09 1.14
ATP 1.09 .99 1.19 1.24 1.26 1.10 1.07
KLA/ATP 1.05 1.06 1.25 1.11 1.13 1.25 1.34
14927508
3
KLA  ATP  ATP+KLA
 149275083 Unknown KLA .74 .68 .68 .77 .71 .85 .69
ATP .85 .69 1.26 .89 .89 1.26 .64
KLA/ATP .64 .63 1.07 .96 1.39 1.07 .82
2610002M
06Rik
KLA  ATP  ATP+KLA
 NM_025921 RIKEN cDNA 2610002M06 gene (2610002M06Rik), mRNA [NM_025921] KLA 2.45 2.54 3.60 3.37 2.67 1.97 1.74
ATP 1.07 1.14 1.40 1.50 1.09 1.37 1.52
KLA/ATP 2.63 2.90 3.39 3.37 2.42 1.72 2.14
2610528K
11Rik
KLA  ATP  ATP+KLA
 NM_175184 RIKEN cDNA 2610528K11 gene (2610528K11Rik), mRNA [NM_175184] KLA .39 .39 .35 .32 .31 .37 .76
ATP .92 1.01 1.11 1.10 .76 .43 .69
KLA/ATP .43 .38 .37 .40 .44 .44 .22
8430408J
07Rik
KLA  ATP  ATP+KLA
 AK018397 16 days embryo lung cDNA, RIKEN full-length enriched library, clone:8430408J07 product:unclassifiable, full insert sequence [AK018397] KLA 1.78 1.64 1.85 1.96 1.52 1.33 1.29
ATP .92 .85 1.08 .84 .60 .62 .70
KLA/ATP 1.50 1.66 1.95 1.41 1.23 .75 .58
Adrb1
KLA  ATP  ATP+KLA
 NM_007419 adrenergic receptor, beta 1 (Adrb1), mRNA [NM_007419] KLA .88 .86 .88 .86 .87 .87 .87
ATP .97 .97 .95 .89 .89 .90 .87
KLA/ATP .90 .88 .91 .84 .91 .79 .82
Adrb2
KLA  ATP  ATP+KLA
 NM_007420 adrenergic receptor, beta 2 (Adrb2), mRNA [NM_007420] KLA .28 .26 .32 .31 .34 .31 .29
ATP 2.09 2.43 2.74 1.72 .96 .63 .29
KLA/ATP .28 .29 .52 .69 .65 .35 .23
Adrbk1
KLA  ATP  ATP+KLA
 NM_130863 adrenergic receptor kinase, beta 1 (Adrbk1), mRNA [NM_130863] KLA .90 .84 .99 1.05 1.52 1.69 1.78
ATP 1.07 1.17 .92 1.19 .76 .60 1.08
KLA/ATP .93 .98 .66 .95 .63 .76 1.59
AK033698
KLA  ATP  ATP+KLA
 AK033698 adult male cecum cDNA, RIKEN full-length enriched library, clone:9130225F20 product:unclassifiable, full insert sequence. [AK033698] KLA .72 .76 .68 .65 .66 .64 .60
ATP 1.10 1.25 1.41 5.92 4.60 1.14 1.19
KLA/ATP .85 .83 .82 2.24 2.21 1.27 .97
AK053285
KLA  ATP  ATP+KLA
 AK053285 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130007F14 product:unclassifiable, full insert sequence. [AK053285] KLA 1.03 1.01 1.01 .94 1.05 .90 .92
ATP .98 1.00 .90 .87 .93 .98 .97
KLA/ATP 1.00 .98 1.01 1.05 .95 1.00 .99
AK053501
KLA  ATP  ATP+KLA
 AK053501 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130103H07 product:inferred: ADP-ribosylation factor-directed GTPase activating protein isoform b {Mus musculus}, full insert sequence. [AK053501] KLA .85 .71 .60 .70 .76 .70 .64
ATP 1.15 1.25 1.21 1.01 .71 .68 1.09
KLA/ATP .86 .89 .67 .72 .64 .55 .83
Ap2a1
KLA  ATP  ATP+KLA
 NM_007458 adaptor protein complex AP-2, alpha 1 subunit (Ap2a1), transcript variant 1, mRNA [NM_007458] KLA .92 1.14 1.16 .91 1.06 1.21 1.21
ATP 1.24 1.66 .77 1.57 1.08 .88 1.32
KLA/ATP 1.36 1.16 .56 1.31 .71 1.02 1.46
Ap2a2
KLA  ATP  ATP+KLA
 NM_007459 adaptor protein complex AP-2, alpha 2 subunit (Ap2a2), mRNA [NM_007459] KLA .89 .90 .92 .77 .91 .83 .86
ATP 1.14 1.15 .86 1.08 .78 .53 1.29
KLA/ATP .94 .98 .67 .85 .54 .51 .99
Ap2b1
KLA  ATP  ATP+KLA
 AK030505 adult male pituitary gland cDNA, RIKEN full-length enriched library, clone:5330422K01 product:adaptor-related protein complex 2, beta 1 subunit, full insert sequence. [AK030505] KLA 1.84 1.44 1.49 1.36 1.58 1.21 1.05
ATP .78 .61 .53 .74 1.81 1.99 1.09
KLA/ATP 1.32 1.13 .92 1.01 2.31 1.59 1.18
Ap2b1
KLA  ATP  ATP+KLA
 NM_001035854 adaptor-related protein complex 2, beta 1 subunit (Ap2b1), transcript variant 1, mRNA [NM_001035854] KLA 2.27 2.24 2.05 2.41 2.07 2.26 1.93
ATP .91 .89 1.02 1.00 .92 2.14 3.06
KLA/ATP 1.94 2.11 2.16 1.95 1.67 1.61 4.01
Ap2m1
KLA  ATP  ATP+KLA
 AK141862 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130035H06 product:adaptor protein complex AP-2, mu1, full insert sequence [AK141862] KLA .80 .69 .92 .86 .81 .97 .67
ATP 1.09 .73 .91 .85 2.29 1.04 .60
KLA/ATP .87 .60 .76 .96 2.66 .86 .59
Ap2m1
KLA  ATP  ATP+KLA
 NM_009679 adaptor protein complex AP-2, mu1 (Ap2m1), mRNA [NM_009679] KLA .81 .86 .90 .77 .88 .92 1.12
ATP 1.06 1.28 .69 .98 .77 .64 1.24
KLA/ATP 1.00 1.03 .51 .87 .54 .67 1.01
Ap2s1
KLA  ATP  ATP+KLA
 NM_198613 adaptor-related protein complex 2, sigma 1 subunit (Ap2s1), mRNA [NM_198613] KLA .91 .94 .95 .87 .96 .98 .82
ATP 1.01 1.09 .66 .94 .67 .64 1.39
KLA/ATP 1.05 1.02 .67 .97 .69 .82 1.19
Arf6
KLA  ATP  ATP+KLA
 NM_007481 ADP-ribosylation factor 6 (Arf6), mRNA [NM_007481] KLA .99 1.01 1.19 1.22 1.41 1.33 1.13
ATP 1.02 1.12 1.06 1.43 1.16 1.12 1.37
KLA/ATP 1.04 1.01 .91 1.32 1.16 1.32 1.52
Arfgap1
KLA  ATP  ATP+KLA
 AK089321 B6-derived CD11 +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F730005E05 product:unclassifiable, full insert sequence [AK089321] KLA .92 .94 .90 .94 1.03 .89 .90
ATP .86 .81 .66 .75 1.03 .96 .97
KLA/ATP .95 .76 .75 .84 .92 .96 1.00
Arfgap1
KLA  ATP  ATP+KLA
 NM_145760 ADP-ribosylation factor GTPase activating protein 1 (Arfgap1), mRNA [NM_145760] KLA 1.21 1.21 1.36 1.38 1.43 1.21 1.17
ATP 1.12 1.14 .94 1.09 .81 1.26 1.42
KLA/ATP 1.31 1.39 1.30 1.25 .84 1.01 1.49
Arfgap2
KLA  ATP  ATP+KLA
 NM_023854 ADP-ribosylation factor GTPase activating protein 2 (Arfgap2), mRNA [NM_023854] KLA 1.23 1.22 1.35 1.12 1.33 1.30 1.23
ATP 1.09 1.18 .88 1.05 .82 1.05 1.32
KLA/ATP 1.36 1.38 .95 1.15 .76 1.06 1.59
Arfgap3
KLA  ATP  ATP+KLA
 AK018680 adult male cecum cDNA, RIKEN full-length enriched library, clone:9130416J18 product:ADP-ribosylation factor GTPase activating protein 3, full insert sequence. [AK018680] KLA 1.06 1.01 .99 1.06 1.06 1.06 1.01
ATP 1.01 1.04 .99 .97 .96 1.07 1.07
KLA/ATP .98 .95 1.06 1.04 1.01 .95 1.03
Arfgap3
KLA  ATP  ATP+KLA
 NM_025445 ADP-ribosylation factor GTPase activating protein 3 (Arfgap3), mRNA [NM_025445] KLA 1.06 .98 1.04 1.28 1.57 1.21 1.04
ATP 1.09 1.04 1.06 .87 1.03 1.40 1.50
KLA/ATP .98 1.04 1.15 .89 1.14 1.21 1.42
Arrb1
KLA  ATP  ATP+KLA
 NM_177231 arrestin, beta 1 (Arrb1), transcript variant a, mRNA [NM_177231] KLA .41 .42 .32 .32 .31 .56 .80
ATP .97 .86 .81 .62 .47 .59 1.16
KLA/ATP .43 .37 .38 .36 .35 .35 .89
BI646741
KLA  ATP  ATP+KLA
 BI646741 gb|BI646741 603279769F1 NCI_CGAP_Mam3 Mus musculus cDNA clone IMAGE:5320025 5, mRNA sequence [BI646741] KLA .55 .54 .47 .54 .65 1.09 1.60
ATP 1.04 .99 .93 1.08 2.49 .79 .88
KLA/ATP .54 .49 .54 .60 1.21 .97 1.54
Cav1
KLA  ATP  ATP+KLA
 NM_007616 caveolin, caveolae protein 1 (Cav1), mRNA [NM_007616] KLA 14.41 13.85 11.14 10.72 9.47 4.26 1.52
ATP 1.05 1.13 1.37 1.72 3.27 15.82 13.01
KLA/ATP 12.62 15.59 16.15 16.68 11.37 8.19 14.27
Cav2
KLA  ATP  ATP+KLA
 NM_016900 caveolin 2 (Cav2), mRNA [NM_016900] KLA 1.04 1.01 .95 .81 .55 .29 .40
ATP 1.08 1.17 1.18 1.18 1.02 .93 .74
KLA/ATP 1.04 1.08 .96 1.13 .62 .28 .57
Cav3
KLA  ATP  ATP+KLA
 NM_007617 caveolin 3 (Cav3), mRNA [NM_007617] KLA 1.01 1.05 1.01 1.08 .97 1.04 1.07
ATP 1.00 1.00 1.03 1.08 1.02 1.08 .98
KLA/ATP 1.05 .98 .83 1.14 1.09 1.10 1.00
Cbl
KLA  ATP  ATP+KLA
 NM_007619 Casitas B-lineage lymphoma (Cbl), mRNA [NM_007619] KLA 1.23 1.22 1.54 1.84 2.25 2.58 2.75
ATP 1.04 1.12 1.07 1.53 1.55 2.12 3.23
KLA/ATP 1.23 1.20 1.22 1.44 1.31 1.88 6.28
Cblb
KLA  ATP  ATP+KLA
 AK045005 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130018P07 product:hypothetical protein, full insert sequence. [AK045005] KLA 1.16 1.11 1.15 1.10 1.16 .98 .93
ATP 1.16 1.23 .98 1.28 1.34 .73 1.55
KLA/ATP 1.26 1.60 1.64 1.23 1.01 .91 1.05
Cblb
KLA  ATP  ATP+KLA
 AK084162 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230004I05 product:unclassifiable, full insert sequence. [AK084162] KLA .97 .98 1.02 1.01 .84 1.02 1.03
ATP 1.03 1.02 .98 1.09 1.05 .96 .96
KLA/ATP 1.07 .95 .91 .98 .98 1.01 1.00
Cblc
KLA  ATP  ATP+KLA
 NM_023224 Casitas B-lineage lymphoma c (Cblc), mRNA [NM_023224] KLA 1.02 .98 1.01 1.02 1.00 .99 1.05
ATP .94 .95 .97 1.04 .99 .97 .99
KLA/ATP 1.00 1.01 .96 .97 .94 .92 .99
Ccr5
KLA  ATP  ATP+KLA
 NM_009917 chemokine (C-C motif) receptor 5 (Ccr5), mRNA [NM_009917] KLA .92 .90 1.34 1.58 1.78 1.69 2.02
ATP 1.09 1.04 1.14 1.01 .71 .62 1.40
KLA/ATP .96 .98 1.28 1.29 1.04 .67 1.57
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Centb1
KLA  ATP  ATP+KLA
 AK133473 11 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:5031407D07 product:centaurin, beta 1, full insert sequence [AK133473] KLA .96 .94 .94 1.01 1.00 .95 .86
ATP 1.04 1.01 1.03 .94 .97 1.03 .94
KLA/ATP .99 .93 .98 .99 1.03 .96 .91
Centb1
KLA  ATP  ATP+KLA
 NM_153788 centaurin, beta 1 (Centb1), mRNA [NM_153788] KLA .80 .79 .74 .71 .65 .63 .55
ATP 1.12 1.18 1.08 1.19 .93 .68 .98
KLA/ATP .87 .86 .73 .82 .66 .65 .65
Centb2
KLA  ATP  ATP+KLA
 NM_030138 centaurin, beta 2 (Centb2), mRNA [NM_030138] KLA 1.14 1.14 1.11 1.10 1.19 1.38 .95
ATP 1.02 1.12 1.15 1.17 2.54 1.68 1.19
KLA/ATP 1.14 1.20 1.24 1.31 2.29 2.30 1.61
Centb5
KLA  ATP  ATP+KLA
 NM_207223 centaurin, beta 5 (Centb5), mRNA [NM_207223] KLA .33 .30 .31 .33 .36 .39 .44
ATP 1.07 1.23 .84 .93 .98 .49 .63
KLA/ATP .35 .32 .28 .35 .50 .42 .34
Centd1
KLA  ATP  ATP+KLA
 BU557601 gb|AGENCOURT_10187243 NIH_MGC_144 Mus musculus cDNA clone IMAGE:6585538 5, mRNA sequence [BU557601] KLA .47 .46 .48 .46 .27 .16 .15
ATP 1.00 1.01 1.17 1.05 .63 1.11 .42
KLA/ATP .46 .51 .52 .63 .32 .37 .24
Centd1
KLA  ATP  ATP+KLA
 XM_132099 gb|PREDICTED: Mus musculus centaurin, delta 1, transcript variant 1 (Centd1), mRNA [XM_132099] KLA .85 .79 .80 .83 .75 .67 .70
ATP 1.10 1.05 .99 .96 .81 .83 .77
KLA/ATP .85 .77 .79 .77 .71 .69 .77
Centd2
KLA  ATP  ATP+KLA
 NM_001040111 centaurin, delta 2 (Centd2), transcript variant 3, mRNA [NM_001040111] KLA 1.56 1.68 1.78 2.20 2.92 2.25 1.78
ATP 1.05 .91 .75 .78 1.09 1.18 1.31
KLA/ATP 1.64 1.50 1.03 1.20 1.24 1.22 1.10
Centd3
KLA  ATP  ATP+KLA
 AK053122 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030006K04 product:PHOSPHOINOSITIDE-BINDING PROTEINS homolog [Homo sapiens], full insert sequence. [AK053122] KLA .74 .71 .70 .79 .77 .61 .59
ATP .93 1.05 .90 .75 .76 .65 .70
KLA/ATP .73 .65 .73 .76 .77 .57 .63
Centd3
KLA  ATP  ATP+KLA
 NM_139206 centaurin, delta 3 (Centd3), mRNA [NM_139206] KLA .26 .21 .16 .11 .07 .05 .10
ATP 1.00 .99 1.00 .79 .46 .22 .24
KLA/ATP .25 .22 .18 .16 .13 .06 .06
Centg1
KLA  ATP  ATP+KLA
 NM_001033263 centaurin, gamma 1 (Centg1), mRNA [NM_001033263] KLA .83 .85 .90 1.00 .86 .88 .76
ATP .98 .99 1.02 .98 .92 .92 .82
KLA/ATP .90 .89 .92 .84 .87 .87 .77
Centg2
KLA  ATP  ATP+KLA
 AK083235 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630030A18 product:hypothetical protein, full insert sequence. [AK083235] KLA .75 .71 .66 .68 .68 .70 .82
ATP .93 .86 .85 .75 .87 .91 1.00
KLA/ATP .68 .68 .83 .66 .85 .86 .84
Centg2
KLA  ATP  ATP+KLA
 NM_178119 centaurin, gamma 2 (Centg2), transcript variant 1, mRNA [NM_178119] KLA 1.08 1.02 .91 .79 .47 .42 .55
ATP .93 .89 1.24 1.17 .90 .68 .82
KLA/ATP 1.05 1.04 1.11 1.01 .91 .74 .62
Centg3
KLA  ATP  ATP+KLA
 NM_139153 centaurin, gamma 3 (Centg3), mRNA [NM_139153] KLA .32 .32 .27 .28 .38 .53 .59
ATP .98 1.01 .97 .95 .89 .74 1.06
KLA/ATP .35 .32 .34 .35 .73 .55 .57
Chmp1a
KLA  ATP  ATP+KLA
 NM_145606 chromatin modifying protein 1A (Chmp1a), mRNA [NM_145606] KLA .77 .82 .86 .89 1.10 1.35 1.21
ATP .95 .96 .87 .87 .79 .91 1.24
KLA/ATP .79 .83 .78 .75 .82 1.00 1.53
Chmp1b
KLA  ATP  ATP+KLA
 NM_024190 chromatin modifying protein 1B (Chmp1b), mRNA [NM_024190] KLA 1.54 1.50 1.67 1.60 1.44 1.35 1.12
ATP .98 1.09 1.25 1.33 1.03 1.31 1.70
KLA/ATP 1.47 1.59 1.77 2.03 1.75 1.77 2.34
Chmp2a
KLA  ATP  ATP+KLA
 NM_026885 chromatin modifying protein 2A (Chmp2a), mRNA [NM_026885] KLA 1.28 1.36 1.32 1.40 1.50 1.61 1.42
ATP .94 1.03 .95 1.30 1.19 .98 1.67
KLA/ATP 1.30 1.40 1.30 1.81 1.70 1.43 2.06
Chmp2b
KLA  ATP  ATP+KLA
 NM_026879 chromatin modifying protein 2B (Chmp2b), mRNA [NM_026879] KLA 1.42 1.37 1.44 1.34 1.21 1.11 .98
ATP .93 1.04 1.24 1.19 1.53 1.53 .94
KLA/ATP 1.27 1.40 1.44 1.70 1.72 1.75 1.13
Chmp4b
KLA  ATP  ATP+KLA
 NM_029362 chromatin modifying protein 4B (Chmp4b), mRNA [NM_029362] KLA 2.12 2.17 2.98 3.23 2.99 3.03 1.90
ATP 1.02 .97 1.38 1.24 1.38 1.62 1.67
KLA/ATP 2.20 2.25 3.46 2.20 2.70 2.77 2.26
Chmp4c
KLA  ATP  ATP+KLA
 AK008733 adult male stomach cDNA, RIKEN full-length enriched library, clone:2210015K02 product:hypothetical protein, full insert sequence [AK008733] KLA 1.03 .96 1.08 .92 .99 .96 1.05
ATP 1.01 .99 1.08 1.05 1.05 1.00 1.00
KLA/ATP .93 1.05 1.13 1.03 1.02 1.02 .90
Chmp4c
KLA  ATP  ATP+KLA
 NM_025519 chromatin modifying protein 4C (Chmp4c), mRNA [NM_025519] KLA 1.07 .97 1.00 1.02 .97 .98 1.04
ATP 1.01 .96 .94 .96 .99 1.00 1.01
KLA/ATP 1.03 1.05 1.01 .98 .99 .99 1.02
Chmp5
KLA  ATP  ATP+KLA
 BC058756 chromatin modifying protein 5, mRNA (cDNA clone IMAGE:6493295) [BC058756] KLA 1.03 1.01 1.02 .99 1.02 1.03 1.04
ATP 1.02 1.02 1.14 1.04 1.02 .99 1.07
KLA/ATP 1.03 1.02 1.02 1.07 1.09 1.01 1.02
Chmp5
KLA  ATP  ATP+KLA
 NM_029814 chromatin modifying protein 5 (Chmp5), mRNA [NM_029814] KLA 1.26 1.26 1.41 1.26 1.40 1.32 1.02
ATP .95 1.01 1.23 1.27 1.02 .95 1.19
KLA/ATP 1.14 1.32 1.53 1.56 1.40 1.30 1.33
Chmp6
KLA  ATP  ATP+KLA
 NM_001085498 chromatin modifying protein 6 (Chmp6), mRNA [NM_001085498] KLA .76 .82 .91 .90 1.20 1.18 1.11
ATP 1.12 1.14 .97 1.01 .60 .74 1.07
KLA/ATP .90 .89 .84 .92 .65 .70 1.04
Chmp7
KLA  ATP  ATP+KLA
 NM_134078 CHMP family, member 7 (Chmp7), mRNA [NM_134078] KLA .80 .70 .75 .83 .74 .82 .93
ATP 1.10 .85 .92 .60 .64 1.32 1.05
KLA/ATP .73 .70 .81 .55 .71 1.17 .95
Clta
KLA  ATP  ATP+KLA
 AK035903 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630016K07 product:unclassifiable, full insert sequence [AK035903] KLA 1.01 1.00 .97 1.02 1.01 1.12 1.09
ATP 1.04 .98 .91 1.05 1.02 1.01 .95
KLA/ATP 1.00 .99 .93 1.07 1.09 .98 .99
Clta
KLA  ATP  ATP+KLA
 NM_016760 clathrin, light polypeptide (Lca) (Clta), transcript variant 3, mRNA [NM_016760] KLA .68 .70 .75 .68 .70 .77 .55
ATP 1.06 1.05 .93 .97 .81 .60 .75
KLA/ATP .75 .76 .68 .71 .69 .64 .42
Cltb
KLA  ATP  ATP+KLA
 NM_028870 clathrin, light polypeptide (Lcb) (Cltb), mRNA [NM_028870] KLA .91 1.01 .97 .78 .71 .52 .73
ATP 1.15 1.32 1.07 1.72 1.96 1.94 1.31
KLA/ATP 1.07 1.17 .76 1.17 1.18 2.12 1.06
Cltc
KLA  ATP  ATP+KLA
 AK039453 adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330045B10 product:CLATHRIN HEAVY CHAIN 1 (CLH-17) homolog [Homo sapiens], full insert sequence. [AK039453] KLA 1.07 1.00 1.01 1.00 1.03 1.06 1.02
ATP 1.00 .99 1.02 .97 1.00 1.02 1.00
KLA/ATP 1.01 1.01 1.02 .98 1.04 .98 .99
Cltc
KLA  ATP  ATP+KLA
 NM_001003908 clathrin, heavy polypeptide (Hc) (Cltc), mRNA [NM_001003908] KLA .94 1.00 .98 .89 1.18 1.02 .93
ATP 1.21 1.42 .72 .89 .93 .96 .75
KLA/ATP 1.12 1.21 .48 .72 .57 .87 .81
Csf1r
KLA  ATP  ATP+KLA
 NM_001037859 colony stimulating factor 1 receptor (Csf1r), mRNA [NM_001037859] KLA .76 .81 .88 .67 .74 .78 .90
ATP 1.10 1.22 .88 1.10 .87 .78 1.28
KLA/ATP .97 .87 .63 .83 .51 .66 1.18
Cxcr4
KLA  ATP  ATP+KLA
 NM_009911 chemokine (C-X-C motif) receptor 4 (Cxcr4), mRNA [NM_009911] KLA .30 .34 .26 .31 .25 .29 .42
ATP 1.27 2.70 6.37 11.61 7.04 1.14 4.92
KLA/ATP .28 .34 .56 2.60 3.47 1.23 1.28
Dab2
KLA  ATP  ATP+KLA
 NM_001037905 disabled homolog 2 (Drosophila) (Dab2), transcript variant 3, mRNA [NM_001037905] KLA .65 .68 .64 .48 .53 .42 .21
ATP 1.12 1.25 .69 .86 .45 .35 .99
KLA/ATP .78 .70 .36 .59 .28 .36 .77
Ddef1
KLA  ATP  ATP+KLA
 AK147689 14 days pregnant adult female placenta cDNA, RIKEN full-length enriched library, clone:M5C1108F01 product:development and differentiation enhancing, full insert sequence [AK147689] KLA 1.39 1.17 .77 .40 .35 .37 .43
ATP 1.06 1.02 .78 .58 .32 .20 .83
KLA/ATP 1.17 1.12 .69 .57 .21 .13 .29
Ddef1
KLA  ATP  ATP+KLA
 NM_010026 development and differentiation enhancing (Ddef1), mRNA [NM_010026] KLA 1.79 1.52 1.41 .70 .52 .56 .58
ATP 1.24 1.13 .78 .83 .57 .40 1.63
KLA/ATP 1.95 1.71 1.07 1.01 .53 .24 1.05
Ddef2
KLA  ATP  ATP+KLA
 NM_001004364 development and differentiation enhancing factor 2 (Ddef2), transcript variant 2, mRNA [NM_001004364] KLA .54 .52 .48 .47 .32 .35 .35
ATP 1.01 1.05 .79 .67 .35 .53 .68
KLA/ATP .51 .52 .53 .45 .31 .40 .40
Ddefl1
KLA  ATP  ATP+KLA
 AK035099 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430088F20 product:hypothetical Ankyrin repeat profile/Serine-rich region/Ankyrin-repeat/Ankyrin repeat region circular profil KLA 3.72 3.96 4.21 2.49 1.30 1.10 1.05
ATP .99 .94 1.10 1.07 .99 1.03 1.04
KLA/ATP 3.11 4.46 3.60 2.53 1.62 1.34 1.08
Dnajc6
KLA  ATP  ATP+KLA
 NM_198412 DnaJ (Hsp40) homolog, subfamily C, member 6 (Dnajc6), mRNA [NM_198412] KLA .95 .98 .94 .97 .94 .95 .92
ATP 1.02 .99 1.01 1.02 .97 1.06 .98
KLA/ATP 1.00 .96 .89 .93 .90 1.09 1.01
Dnm1
KLA  ATP  ATP+KLA
 NM_010065 dynamin 1 (Dnm1), mRNA [NM_010065] KLA .96 .92 .87 .88 .85 .79 1.16
ATP 1.05 1.08 .96 1.04 .93 .80 1.59
KLA/ATP .99 1.00 .82 .93 .79 .79 1.24
Dnm2
KLA  ATP  ATP+KLA
 NM_001039520 dynamin 2 (Dnm2), mRNA [NM_001039520] KLA 1.00 1.03 1.14 1.01 1.29 1.47 1.30
ATP 1.11 1.31 .93 1.41 1.04 .90 1.53
KLA/ATP 1.26 1.23 .87 1.41 .86 .98 1.86
Dnm3
KLA  ATP  ATP+KLA
 NM_001038619 dynamin 3 (Dnm3), mRNA [NM_001038619] KLA 1.00 1.01 1.02 1.02 1.03 .96 1.04
ATP 1.05 1.01 .99 .96 1.03 .97 .88
KLA/ATP 1.03 1.05 1.03 .99 .98 1.02 1.03
Eea1
KLA  ATP  ATP+KLA
 NM_001001932 early endosome antigen 1 (Eea1), mRNA [NM_001001932] KLA .88 .83 .77 .79 1.02 .99 .86
ATP 1.09 1.19 1.09 1.47 1.83 1.20 .99
KLA/ATP .92 .90 .82 1.05 1.17 1.03 .82
Egf
KLA  ATP  ATP+KLA
 NM_010113 epidermal growth factor (Egf), mRNA [NM_010113] KLA .89 .90 .81 .83 .83 .86 .92
ATP 1.03 1.03 .95 .84 .67 .79 .88
KLA/ATP .86 .86 .77 .77 .69 .78 .83
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Ehd1
KLA  ATP  ATP+KLA
 NM_010119 EH-domain containing 1 (Ehd1), mRNA [NM_010119] KLA 7.81 7.90 6.69 7.15 7.68 8.74 5.98
ATP 1.03 .96 1.24 1.82 3.12 7.19 7.25
KLA/ATP 7.84 7.48 7.34 6.53 6.28 5.51 13.47
Ehd2
KLA  ATP  ATP+KLA
 BC020014 EH-domain containing 2, mRNA (cDNA clone IMAGE:3501385), partial cds [BC020014] KLA 1.02 1.02 .99 .98 .99 .97 .93
ATP 1.07 1.01 .98 .91 .99 .99 .91
KLA/ATP 1.10 1.07 1.05 .95 .97 .93 1.01
Ehd2
KLA  ATP  ATP+KLA
 NM_153068 EH-domain containing 2 (Ehd2), mRNA [NM_153068] KLA 1.02 1.15 1.15 1.05 1.19 1.04 1.05
ATP 1.03 1.06 1.02 1.03 .98 1.05 1.10
KLA/ATP 1.09 1.12 1.02 1.06 1.04 1.07 1.12
Ehd3
KLA  ATP  ATP+KLA
 NM_020578 EH-domain containing 3 (Ehd3), mRNA [NM_020578] KLA 1.57 1.67 1.77 2.01 1.90 1.41 1.04
ATP .93 .99 1.01 .93 .94 .93 1.08
KLA/ATP 1.50 1.62 1.59 1.45 1.14 1.11 1.04
Ehd4
KLA  ATP  ATP+KLA
 NM_133838 EH-domain containing 4 (Ehd4), mRNA [NM_133838] KLA .82 .77 1.15 1.30 1.25 1.27 .63
ATP 1.09 .92 1.09 .66 .49 .43 .77
KLA/ATP .80 .81 1.29 .72 .95 .84 .74
Epn1
KLA  ATP  ATP+KLA
 NM_010147 epsin 1 (Epn1), mRNA [NM_010147] KLA .78 .81 .76 .69 .76 .86 .93
ATP 1.13 1.32 .83 1.09 .72 .67 1.25
KLA/ATP .86 .83 .54 .69 .46 .62 1.24
Epn2
KLA  ATP  ATP+KLA
 NM_010148 epsin 2 (Epn2), mRNA [NM_010148] KLA .40 .41 .42 .45 .41 .51 .80
ATP .94 .94 1.05 1.06 1.04 1.09 1.15
KLA/ATP .44 .42 .64 .71 .77 .69 .61
Epn3
KLA  ATP  ATP+KLA
 NM_027984 epsin 3 (Epn3), mRNA [NM_027984] KLA 1.06 1.02 1.02 1.00 1.11 1.13 .99
ATP .98 .99 1.03 1.14 1.16 1.04 1.08
KLA/ATP 1.08 1.10 1.13 1.18 1.25 1.18 1.25
Eps15
KLA  ATP  ATP+KLA
 BC048783 epidermal growth factor receptor pathway substrate 15, mRNA (cDNA clone MGC:54717 IMAGE:6466448), complete cds [BC048783] KLA .87 .80 .77 .71 .59 .54 .46
ATP .92 .89 .97 .65 .54 .34 .57
KLA/ATP .81 .80 .75 .52 .47 .31 .33
Eps15
KLA  ATP  ATP+KLA
 NM_007943 epidermal growth factor receptor pathway substrate 15 (Eps15), mRNA [NM_007943] KLA 1.54 1.45 1.26 1.30 1.12 .78 .93
ATP 1.17 1.24 1.05 1.08 .76 .95 2.59
KLA/ATP 1.22 1.41 1.22 1.51 .81 .60 2.03
Erbb3
KLA  ATP  ATP+KLA
 BC049279 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian), mRNA (cDNA clone IMAGE:4460595), partial cds. [BC049279] KLA .71 .74 .77 .92 1.26 1.39 1.01
ATP .92 .90 .92 .70 .43 .93 1.08
KLA/ATP .66 .70 .71 .61 .56 1.15 1.29
Erbb3
KLA  ATP  ATP+KLA
 NM_010153 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (Erbb3), mRNA [NM_010153] KLA .98 .99 .98 .98 .98 1.03 1.01
ATP 1.01 1.00 .95 1.00 .94 .95 1.01
KLA/ATP .98 1.03 .95 .99 .99 .99 .93
Erbb4
KLA  ATP  ATP+KLA
 NM_010154 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) (Erbb4), mRNA [NM_010154] KLA 1.06 .98 .93 .99 1.02 .98 .91
ATP 1.01 .97 .93 .96 1.00 1.01 1.01
KLA/ATP .94 .96 1.03 .99 .87 .95 1.02
F2r
KLA  ATP  ATP+KLA
 NM_010169 coagulation factor II (thrombin) receptor (F2r), mRNA [NM_010169] KLA 3.73 3.81 3.68 3.00 2.75 1.49 1.01
ATP .98 1.02 1.25 1.24 1.31 1.63 1.16
KLA/ATP 3.51 4.05 3.49 3.00 2.48 1.69 1.23
Fgfr2
KLA  ATP  ATP+KLA
 NM_010207 fibroblast growth factor receptor 2 (Fgfr2), transcript variant 1, mRNA [NM_010207] KLA 1.01 .98 1.00 1.01 .98 1.00 .99
ATP 1.00 1.03 1.05 1.03 1.01 1.01 1.00
KLA/ATP 1.00 1.01 1.04 1.01 .99 1.02 1.03
Fgfr3
KLA  ATP  ATP+KLA
 NM_008010 fibroblast growth factor receptor 3 (Fgfr3), mRNA [NM_008010] KLA 1.09 1.15 1.05 1.10 1.02 1.05 1.12
ATP 1.05 .94 .98 .87 .91 .95 .92
KLA/ATP 1.13 1.11 1.10 .91 .92 .93 .92
Fgfr4
KLA  ATP  ATP+KLA
 AF127140 fibroblast growth factor receptor 4 splice variant 17b (Fgfr4) mRNA, partial cds. [AF127140] KLA .96 .97 1.06 .97 1.05 1.05 1.08
ATP 1.02 .98 1.07 1.23 1.15 1.18 1.31
KLA/ATP .91 1.02 1.08 1.16 1.07 1.05 1.23
Fgfr4
KLA  ATP  ATP+KLA
 NM_008011 fibroblast growth factor receptor 4 (Fgfr4), mRNA [NM_008011] KLA 1.08 1.11 1.09 1.06 .99 1.06 1.03
ATP 1.05 .96 1.17 1.06 1.10 1.04 1.01
KLA/ATP 1.03 .98 1.10 1.06 1.05 1.06 1.04
Flt1
KLA  ATP  ATP+KLA
 NM_010228 FMS-like tyrosine kinase 1 (Flt1), mRNA [NM_010228] KLA 3.02 2.74 2.92 3.54 3.71 3.82 1.43
ATP .88 .85 1.07 .85 .94 1.31 1.16
KLA/ATP 2.60 2.99 3.08 2.13 2.23 2.00 2.59
Folr1
KLA  ATP  ATP+KLA
 NM_008034 folate receptor 1 (adult) (Folr1), mRNA [NM_008034] KLA 1.34 1.26 1.21 1.23 1.21 1.16 .86
ATP 1.04 1.04 1.27 1.13 1.17 1.22 1.18
KLA/ATP 1.15 1.31 1.59 1.34 1.33 1.32 1.40
Folr2
KLA  ATP  ATP+KLA
 NM_008035 folate receptor 2 (fetal) (Folr2), mRNA [NM_008035] KLA .89 .98 .94 .78 .86 .78 .86
ATP 1.01 1.06 .82 .93 .81 .65 1.10
KLA/ATP 1.08 1.03 .76 .96 .74 .69 1.04
Folr4
KLA  ATP  ATP+KLA
 NM_176807 folate receptor 4 (delta) (Folr4), transcript variant 2, mRNA [NM_176807] KLA .87 .91 .92 1.05 1.04 .93 .94
ATP 1.18 1.27 1.02 1.02 .89 .94 .98
KLA/ATP .98 .96 .98 .93 .89 .86 .92
Git1
KLA  ATP  ATP+KLA
 NM_001004144 G protein-coupled receptor kinase-interactor 1 (Git1), mRNA [NM_001004144] KLA .95 1.03 1.19 .93 1.13 1.05 1.26
ATP 1.14 1.52 .93 1.50 1.64 1.24 1.68
KLA/ATP 1.29 1.28 .74 1.31 1.07 1.32 1.88
Git2
KLA  ATP  ATP+KLA
 AK005365 adult male cerebellum cDNA, RIKEN full-length enriched library, clone:1500036H07 product:weakly similar to ARF GTPASE-ACTIVATING PROTEIN GIT2 (G PROTEIN-COUPLED RECEPTOR KINASE-INTERACTOR 2) (TYROSINE-PHOSPHORYLATED PROTEIN CAT-2) [Mus mu KLA .88 .84 .84 .80 .88 .98 .98
ATP .95 1.09 .97 1.11 1.10 .79 .99
KLA/ATP .86 .84 .81 .90 .79 .79 1.02
Git2
KLA  ATP  ATP+KLA
 AK017943 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830420E16 product:G protein-coupled receptor kinase-interactor 2, full insert sequence. [AK017943] KLA .83 .77 .76 .73 .90 .84 .84
ATP .99 1.00 .73 1.10 .89 .71 .89
KLA/ATP .75 .72 .62 .90 .80 .72 .82
Git2
KLA  ATP  ATP+KLA
 NM_019834 G protein-coupled receptor kinase-interactor 2 (Git2), transcript variant 1, mRNA [NM_019834] KLA .65 .66 .62 .68 .89 .90 .88
ATP 1.06 1.06 .98 1.23 1.53 .74 .79
KLA/ATP .74 .70 .62 .92 1.23 .83 .91
Grk1
KLA  ATP  ATP+KLA
 NM_011881 G protein-coupled receptor kinase 1 (Grk1), mRNA [NM_011881] KLA 1.10 1.03 .96 .96 1.08 .98 1.01
ATP 1.04 .99 .95 1.04 1.03 .96 1.06
KLA/ATP .99 1.05 .95 1.02 1.05 1.02 1.06
Grk4
KLA  ATP  ATP+KLA
 NM_019497 G protein-coupled receptor kinase 4 (Grk4), transcript variant 1, mRNA [NM_019497] KLA 1.05 1.03 .98 1.16 .96 .95 .95
ATP .95 .97 1.12 1.09 .93 .95 1.13
KLA/ATP 1.04 1.05 1.14 1.04 .95 .97 1.03
Grk5
KLA  ATP  ATP+KLA
 NM_018869 G protein-coupled receptor kinase 5 (Grk5), mRNA [NM_018869] KLA 1.38 1.35 1.36 1.01 .70 .60 1.49
ATP .96 .99 1.20 1.19 .81 2.59 1.98
KLA/ATP 1.35 1.31 1.41 1.23 .68 1.16 2.94
Grk6
KLA  ATP  ATP+KLA
 NM_001038018 G protein-coupled receptor kinase 6 (Grk6), transcript variant 1, mRNA [NM_001038018] KLA .41 .46 .43 .47 .69 .79 .75
ATP 1.03 1.09 .81 .90 .61 .65 .50
KLA/ATP .48 .45 .36 .43 .40 .54 .40
Grk6
KLA  ATP  ATP+KLA
 NM_011938 G protein-coupled receptor kinase 6 (Grk6), transcript variant 2, mRNA [NM_011938] KLA .71 .72 .69 .71 .82 .94 .80
ATP 1.04 1.15 .93 1.06 .69 .78 .65
KLA/ATP .74 .70 .65 .70 .56 .72 .55
H2-Bl
KLA  ATP  ATP+KLA
 NM_008199 histocompatibility 2, blastocyst (H2-Bl), mRNA [NM_008199] KLA 1.29 1.32 1.40 1.28 1.36 1.46 1.80
ATP 1.04 1.11 1.02 1.34 1.28 1.32 1.47
KLA/ATP 1.32 1.39 1.34 1.77 1.41 1.61 2.39
H2-D1
KLA  ATP  ATP+KLA
 AK169750 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430019E13 product:histocompatibility 2, D region locus 1, full insert sequence [AK169750] KLA .99 .98 .96 .99 .93 .91 .94
ATP .96 1.01 1.02 .95 1.05 1.00 .98
KLA/ATP .92 .94 .97 .97 .98 .92 1.03
H2-D1
KLA  ATP  ATP+KLA
 NM_010380 histocompatibility 2, D region locus 1 (H2-D1), mRNA [NM_010380] KLA 1.38 1.45 1.73 1.42 1.70 1.76 2.56
ATP 1.15 1.11 .86 1.12 1.19 1.28 1.90
KLA/ATP 1.58 1.72 1.38 1.56 1.38 1.69 3.21
H2-K1
KLA  ATP  ATP+KLA
 M69070 mRNA, complete cds. [M69070] KLA 1.76 1.66 1.78 1.78 1.87 2.23 2.99
ATP .98 .97 1.19 1.45 1.36 1.68 2.17
KLA/ATP 1.68 1.70 1.87 1.96 1.87 2.13 3.82
H2-K1
KLA  ATP  ATP+KLA
 NM_001001892 histocompatibility 2, K1, K region (H2-K1), transcript variant 1, mRNA [NM_001001892] KLA 1.82 1.66 1.73 1.76 1.87 2.29 3.17
ATP .98 .97 1.13 1.32 1.29 1.57 2.09
KLA/ATP 1.64 1.71 1.77 1.82 1.71 2.12 3.91
H2-M1
KLA  ATP  ATP+KLA
 NM_177636 histocompatibility 2, M region locus 1 (H2-M1), mRNA [NM_177636] KLA .99 1.01 1.02 1.02 .97 1.03 1.04
ATP 1.01 .99 1.03 1.07 .92 1.03 .98
KLA/ATP 1.08 .97 .94 1.04 1.00 1.04 1.02
H2-M10.1
KLA  ATP  ATP+KLA
 NM_013544 histocompatibility 2, M region locus 10.1 (H2-M10.1), mRNA [NM_013544] KLA 1.04 1.00 1.05 .95 .98 1.04 .94
ATP 1.06 1.04 .96 .95 .97 .98 .98
KLA/ATP 1.02 1.07 .98 1.02 .92 .92 .99
H2-M10.2
KLA  ATP  ATP+KLA
 NM_177923 histocompatibility 2, M region locus 10.2 (H2-M10.2), mRNA [NM_177923] KLA 2.18 2.23 2.51 2.61 2.90 3.30 3.40
ATP 1.08 1.02 1.22 1.39 1.30 1.56 2.66
KLA/ATP 2.23 2.53 2.82 2.91 2.89 2.60 3.92
H2-M10.3
KLA  ATP  ATP+KLA
 AY211080 major histocompatibility complex class Ib M10.3 mRNA, complete cds [AY211080] KLA .95 1.08 .99 .95 1.00 1.11 1.04
ATP .98 .96 1.00 .99 1.00 .99 1.00
KLA/ATP 1.00 .99 1.00 1.00 .99 .96 1.03
H2-M10.4
KLA  ATP  ATP+KLA
 NM_177634 histocompatibility 2, M region locus 10.4 (H2-M10.4), mRNA [NM_177634] KLA 1.03 1.04 1.08 1.08 1.04 1.03 1.03
ATP 1.07 1.05 .97 1.08 .95 .97 1.02
KLA/ATP 1.02 .97 1.02 .99 .93 1.06 1.04
H2-M10.5
KLA  ATP  ATP+KLA
 NM_177637 histocompatibility 2, M region locus 10.5 (H2-M10.5), mRNA [NM_177637] KLA 1.00 1.04 1.13 .93 .99 1.00 1.07
ATP 1.02 1.02 1.04 .90 1.03 .99 .99
KLA/ATP 1.06 1.03 .97 1.03 1.03 .98 1.04
H2-M10.6
KLA  ATP  ATP+KLA
 NM_201611 histocompatibility 2, M region locus 10.6 (H2-M10.6), mRNA [NM_201611] KLA 1.06 .99 1.04 1.06 .98 1.03 .92
ATP 1.04 1.09 .96 .98 .94 1.07 .98
KLA/ATP 1.01 1.06 1.02 .96 .96 1.04 1.05
H2-M11
KLA  ATP  ATP+KLA
 NM_177635 histocompatibility 2, M region locus 11 (H2-M11), mRNA [NM_177635] KLA 1.03 1.07 1.06 1.02 .96 1.05 1.03
ATP 1.02 .96 1.08 .98 1.04 .94 .98
KLA/ATP 1.03 1.03 .99 1.01 1.01 .98 .99
H2-M3
KLA  ATP  ATP+KLA
 NM_013819 histocompatibility 2, M region locus 3 (H2-M3), mRNA [NM_013819] KLA 1.90 2.04 2.09 2.37 2.30 2.56 2.73
ATP 1.00 1.00 1.19 1.34 1.00 .70 1.09
KLA/ATP 1.77 1.94 2.37 2.49 1.89 1.67 2.06
H2-M9
KLA  ATP  ATP+KLA
 NM_008205 histocompatibility 2, M region locus 9 (H2-M9), mRNA [NM_008205] KLA 1.03 .99 .96 .98 1.01 .99 1.03
ATP .96 1.06 .94 .96 1.05 1.06 1.00
KLA/ATP .96 1.01 1.01 .99 .97 .95 .98
H2-Q1
KLA  ATP  ATP+KLA
 NM_010390 histocompatibility 2, Q region locus 1 (H2-Q1), mRNA [NM_010390] KLA 1.05 1.08 1.03 1.02 .98 1.09 1.00
ATP .99 .92 .93 1.01 1.01 1.04 1.00
KLA/ATP 1.07 1.00 1.00 .91 .97 1.07 1.04
H2-Q10
KLA  ATP  ATP+KLA
 NM_010391 histocompatibility 2, Q region locus 10 (H2-Q10), mRNA [NM_010391] KLA 1.50 1.50 1.70 1.64 1.67 1.79 2.18
ATP 1.12 1.11 1.09 1.46 1.42 1.43 1.69
KLA/ATP 1.61 1.72 1.79 1.94 1.81 1.81 2.93
H2-Q2
KLA  ATP  ATP+KLA
 NM_010392 histocompatibility 2, Q region locus 2 (H2-Q2), mRNA [NM_010392] KLA 1.55 1.52 1.61 1.45 1.83 1.94 2.47
ATP 1.09 1.13 .92 1.16 1.17 1.30 1.88
KLA/ATP 1.55 1.70 1.58 1.80 1.64 1.87 3.43
H2-Q7
KLA  ATP  ATP+KLA
 NM_010394 histocompatibility 2, Q region locus 7 (H2-Q7), mRNA [NM_010394] KLA 1.57 1.58 1.74 1.55 1.82 2.00 2.76
ATP 1.05 1.09 .84 1.12 1.12 1.23 2.00
KLA/ATP 1.63 1.75 1.43 1.67 1.53 1.80 3.48
H2-Q8
KLA  ATP  ATP+KLA
 NM_023124 histocompatibility 2, Q region locus 8 (H2-Q8), mRNA [NM_023124] KLA 7.48 6.46 6.41 7.15 7.46 9.60 18.27
ATP 1.01 .98 1.48 2.05 1.93 3.83 8.26
KLA/ATP 6.72 7.10 9.11 10.95 10.71 12.88 31.43
H2-T22
KLA  ATP  ATP+KLA
 NM_010397 histocompatibility 2, T region locus 22 (H2-T22), mRNA [NM_010397] KLA 5.21 5.40 5.81 6.31 7.42 9.49 7.50
ATP 1.01 .95 .88 .92 .93 3.65 5.53
KLA/ATP 4.83 5.12 4.58 4.74 4.81 6.89 14.89
H2-T23
KLA  ATP  ATP+KLA
 NM_010398 histocompatibility 2, T region locus 23 (H2-T23), mRNA [NM_010398] KLA 1.83 1.80 1.92 1.86 2.32 2.56 3.43
ATP 1.03 1.08 .85 1.18 1.09 1.30 2.49
KLA/ATP 1.76 1.92 1.62 1.93 1.76 2.13 4.06
H2-T24
KLA  ATP  ATP+KLA
 NM_008207 histocompatibility 2, T region locus 24 (H2-T24), mRNA [NM_008207] KLA 3.02 3.26 4.14 4.26 5.15 6.06 5.89
ATP 1.08 1.09 1.32 1.35 1.17 1.71 6.71
KLA/ATP 3.23 3.31 3.54 3.85 3.07 3.73 9.10
H2-T3
KLA  ATP  ATP+KLA
 NM_008208 histocompatibility 2, T region locus 3 (H2-T3), mRNA [NM_008208] KLA .95 1.04 1.00 .97 .97 .99 1.00
ATP .98 1.08 1.03 1.01 .98 1.02 1.03
KLA/ATP 1.05 .96 1.02 1.04 1.05 1.00 .97
Hgs
KLA  ATP  ATP+KLA
 NM_008244 HGF-regulated tyrosine kinase substrate (Hgs), mRNA [NM_008244] KLA 1.04 1.12 1.07 1.23 1.69 1.57 1.56
ATP 1.08 1.21 .92 1.20 1.45 2.05 1.41
KLA/ATP 1.12 1.30 .99 1.25 1.38 2.04 2.14
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Hspa1a
KLA  ATP  ATP+KLA
 NM_010479 heat shock protein 1A (Hspa1a), mRNA [NM_010479] KLA 7.88 6.99 4.47 5.18 7.81 11.47 4.14
ATP 1.88 5.62 43.42 58.76 55.53 28.89 9.13
KLA/ATP 7.40 7.62 28.23 54.12 70.14 43.09 22.49
Hspa1b
KLA  ATP  ATP+KLA
 NM_010478 heat shock protein 1B (Hspa1b), mRNA [NM_010478] KLA 5.01 4.73 3.77 3.62 4.81 6.53 3.12
ATP 1.34 3.07 14.11 17.14 17.51 11.21 4.82
KLA/ATP 5.04 5.15 11.63 19.94 20.84 15.79 9.30
Hspa1l
KLA  ATP  ATP+KLA
 NM_013558 heat shock protein 1-like (Hspa1l), mRNA [NM_013558] KLA .98 1.04 1.10 1.21 1.51 1.97 1.86
ATP 1.03 1.08 1.07 1.14 .93 1.21 1.89
KLA/ATP 1.06 1.01 .99 1.09 .97 1.39 2.87
Hspa2
KLA  ATP  ATP+KLA
 NM_008301 heat shock protein 2 (Hspa2), transcript variant 1, mRNA [NM_008301] KLA .98 .97 1.12 1.23 1.20 1.72 1.38
ATP 1.01 1.10 1.45 3.12 2.45 1.98 .98
KLA/ATP .99 1.12 1.52 2.60 2.89 2.62 1.18
Hspa8
KLA  ATP  ATP+KLA
 NM_031165 heat shock protein 8 (Hspa8), mRNA [NM_031165] KLA 1.00 .98 1.27 1.18 1.45 1.60 1.31
ATP 1.22 1.18 1.07 1.44 1.07 .53 .57
KLA/ATP 1.18 1.22 1.14 1.08 .93 .82 .77
Igf1r
KLA  ATP  ATP+KLA
 NM_010513 insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] KLA 1.32 1.32 1.08 .91 .55 .48 .45
ATP 1.03 1.06 1.06 1.29 1.31 1.45 .47
KLA/ATP 1.30 1.37 1.11 1.00 .93 1.02 .45
Il2ra
KLA  ATP  ATP+KLA
 AF054581 interleukin 2 receptor mRNA, 3UTR, partial sequence. [AF054581] KLA 1.76 2.05 2.73 2.46 3.58 2.68 1.13
ATP .99 .99 1.00 1.09 1.13 1.14 1.03
KLA/ATP 1.93 2.11 1.32 2.27 1.87 2.13 1.37
Il2ra
KLA  ATP  ATP+KLA
 NM_008367 interleukin 2 receptor, alpha chain (Il2ra), mRNA [NM_008367] KLA 1.33 1.29 1.46 1.43 1.82 1.57 1.15
ATP 1.02 1.03 1.01 1.02 1.01 1.12 1.05
KLA/ATP 1.30 1.46 1.36 1.41 1.22 1.47 1.66
Il2rb
KLA  ATP  ATP+KLA
 NM_008368 interleukin 2 receptor, beta chain (Il2rb), mRNA [NM_008368] KLA .92 1.00 1.00 1.00 .91 .98 1.09
ATP 1.02 .98 1.00 .95 1.02 1.04 1.04
KLA/ATP 1.03 .98 1.01 .99 .94 1.13 1.00
Il2rg
KLA  ATP  ATP+KLA
 NM_013563 interleukin 2 receptor, gamma chain (Il2rg), mRNA [NM_013563] KLA 2.97 2.92 3.73 3.39 4.04 3.45 4.83
ATP 1.25 1.41 1.04 1.82 1.48 1.12 2.89
KLA/ATP 3.65 4.34 2.42 4.70 2.62 2.54 5.15
Il8ra
KLA  ATP  ATP+KLA
 NM_178241 interleukin 8 receptor, alpha (Il8ra), mRNA [NM_178241] KLA .96 1.09 1.01 1.02 .92 .93 .95
ATP .95 .99 .88 .99 1.02 1.02 .96
KLA/ATP 1.01 1.03 .92 .99 1.02 1.02 1.00
Il8rb
KLA  ATP  ATP+KLA
 NM_009909 interleukin 8 receptor, beta (Il8rb), mRNA [NM_009909] KLA 1.05 1.01 1.06 .98 1.06 1.06 .85
ATP .98 .96 .99 .94 .98 .96 1.05
KLA/ATP 1.01 .93 1.04 .92 .98 .98 .99
Iqsec1
KLA  ATP  ATP+KLA
 AK166886 blastocyst blastocyst cDNA, RIKEN full-length enriched library, clone:I1C0020J06 product:unclassifiable, full insert sequence [AK166886] KLA .42 .41 .38 .44 .61 .73 .65
ATP 1.01 .90 1.04 1.01 1.68 1.27 1.09
KLA/ATP .42 .38 .44 .57 1.09 1.15 .57
Iqsec1
KLA  ATP  ATP+KLA
 XM_001480423 gb|PREDICTED: Mus musculus IQ motif and Sec7 domain 1 (Iqsec1), mRNA [XM_001480423] KLA .46 .47 .43 .51 .71 .84 .78
ATP 1.07 1.12 1.06 1.52 2.15 1.44 1.60
KLA/ATP .53 .48 .54 .71 1.30 1.71 1.31
Iqsec3
KLA  ATP  ATP+KLA
 NM_001033354 IQ motif and Sec7 domain 3 (Iqsec3), mRNA [NM_001033354] KLA 1.02 .97 1.00 .97 1.02 1.08 1.03
ATP .92 1.00 1.04 .99 .99 1.04 1.01
KLA/ATP .98 .89 1.12 .95 .96 1.00 1.02
Itch
KLA  ATP  ATP+KLA
 AK033318 15 days embryo male testis cDNA, RIKEN full-length enriched library, clone:8030492O04 product:unclassifiable, full insert sequence. [AK033318] KLA .94 .82 .94 .88 1.04 .93 .95
ATP 1.15 1.14 .93 .75 1.42 1.04 .99
KLA/ATP .98 .95 .86 .75 1.25 1.01 .96
Itch
KLA  ATP  ATP+KLA
 AK038333 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130096D14 product:similar to TYROSINE-PROTEIN KINASE JAK3 (EC 2.7.1.112) (JANUS KINASE 3) (JAK-3) [Mus musculus], full insert sequence. [AK038333] KLA .97 .89 .88 .89 .97 .87 .94
ATP 1.03 .87 .72 .90 1.16 1.01 .93
KLA/ATP .94 .89 .83 .80 .94 .93 .93
Itch
KLA  ATP  ATP+KLA
 AK220164 mRNA for mKIAA4011 protein [AK220164] KLA 1.08 .99 1.04 1.13 .99 .99 1.06
ATP .95 .92 1.13 .73 .96 1.33 .93
KLA/ATP .94 .97 1.12 .75 1.10 1.40 1.11
Itch
KLA  ATP  ATP+KLA
 NM_008395 itchy, E3 ubiquitin protein ligase (Itch), mRNA [NM_008395] KLA 1.06 1.01 1.13 1.05 1.00 1.08 1.13
ATP 1.02 1.10 .96 1.02 1.07 1.06 1.22
KLA/ATP 1.07 1.00 .93 1.01 .95 1.10 1.29
Kdr
KLA  ATP  ATP+KLA
 AK054510 2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330034B14 product:kinase insert domain protein receptor, full insert sequence. [AK054510] KLA 1.00 1.00 .98 1.03 1.02 1.00 .99
ATP .99 1.00 1.00 1.02 1.00 1.00 1.00
KLA/ATP 1.01 1.02 1.03 1.02 .98 1.00 1.01
Kdr
KLA  ATP  ATP+KLA
 NM_010612 kinase insert domain protein receptor (Kdr), mRNA [NM_010612] KLA 7.30 7.28 6.48 6.79 5.97 6.18 2.71
ATP 1.00 .84 1.06 1.14 3.62 3.10 7.15
KLA/ATP 6.62 7.17 7.12 6.48 14.11 12.63 11.01
Kit
KLA  ATP  ATP+KLA
 Y00864 gb|Mouse c-kit mRNA. [Y00864] KLA .88 .86 .83 .76 .75 .73 .87
ATP 1.06 1.07 1.03 1.04 3.95 1.93 1.25
KLA/ATP .87 .87 .89 .89 1.06 1.08 .91
Ldlr
KLA  ATP  ATP+KLA
 NM_010700 low density lipoprotein receptor (Ldlr), mRNA [NM_010700] KLA 2.17 2.00 2.07 1.87 1.38 .78 1.00
ATP .98 .87 1.53 1.14 1.01 1.52 1.60
KLA/ATP 1.86 1.76 2.52 1.55 1.59 .84 .82
Ldlr
KLA  ATP  ATP+KLA
 Z19521 gb|M.musculus Ldlr mRNA encoding low density lipoprotein receptor. [Z19521] KLA 1.94 1.93 2.24 2.01 1.73 1.08 1.26
ATP 1.12 1.21 1.47 1.65 1.28 1.45 1.67
KLA/ATP 2.22 2.28 2.17 2.27 1.50 1.13 1.29
Ldlrap1
KLA  ATP  ATP+KLA
 NM_145554 low density lipoprotein receptor adaptor protein 1 (Ldlrap1), mRNA [NM_145554] KLA .17 .16 .19 .23 .44 1.06 1.02
ATP 1.18 1.23 .84 .80 .72 .73 1.70
KLA/ATP .17 .17 .19 .23 .57 .82 2.34
LOC67670
8
KLA  ATP  ATP+KLA
 XM_992322 ref|PREDICTED: Mus musculus similar to class I (Qa) Q2k antigen (LOC676708), mRNA [XM_992322] KLA 2.18 2.22 2.32 2.27 2.28 2.77 3.62
ATP 1.04 1.17 1.17 2.19 1.83 1.75 2.30
KLA/ATP 2.20 2.44 2.25 3.41 2.30 2.63 5.00
Mdm2
KLA  ATP  ATP+KLA
 NM_010786 transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA [NM_010786] KLA 1.77 1.59 1.98 1.51 1.77 1.60 1.77
ATP 1.01 1.21 1.36 3.24 5.04 2.08 1.36
KLA/ATP 1.89 1.86 2.93 5.65 5.98 2.78 2.64
Met
KLA  ATP  ATP+KLA
 NM_008591 met proto-oncogene (Met), mRNA [NM_008591] KLA 3.56 3.71 3.68 3.79 4.24 5.89 6.95
ATP .98 .96 1.16 1.21 3.32 12.98 6.60
KLA/ATP 3.75 3.80 3.58 3.28 3.69 4.27 14.22
Mm.11707
6
KLA  ATP  ATP+KLA
 124001565 Unknown KLA .78 .79 .79 .78 .79 .68 .78
ATP 1.04 1.01 1.18 .95 .89 1.00 1.32
KLA/ATP .80 .88 .95 .83 .85 .85 .83
Mm.14360
3
KLA  ATP  ATP+KLA
 31560791 Unknown KLA 1.07 .96 1.05 1.03 1.00 1.01 .95
ATP 1.01 1.08 1.06 .97 1.03 .98 1.03
KLA/ATP 1.03 1.04 1.07 .99 .92 .94 .96
Mm.19506
1
KLA  ATP  ATP+KLA
 76253707 Unknown KLA 5.35 4.83 5.36 6.20 6.87 9.80 7.83
ATP .97 .90 .96 .77 .80 3.98 5.87
KLA/ATP 4.63 4.51 4.51 3.75 4.39 7.21 16.38
Mm.20374
7
KLA  ATP  ATP+KLA
 146149233 Unknown KLA .34 .30 .28 .41 .80 1.31 1.29
ATP .93 .83 .82 .76 .43 .46 .88
KLA/ATP .30 .28 .27 .27 .27 .51 1.11
Mm.23446
6
KLA  ATP  ATP+KLA
 87299639 Unknown KLA .92 1.02 1.03 1.00 1.00 1.10 1.07
ATP 1.03 1.01 1.12 .94 1.03 .91 1.01
KLA/ATP .98 1.00 1.03 1.05 1.04 1.11 1.03
Mm.24167
KLA  ATP  ATP+KLA
 142351808 Unknown KLA 1.18 1.08 1.12 1.17 1.12 1.16 1.05
ATP .97 .97 1.12 .98 .93 1.08 1.02
KLA/ATP 1.16 1.17 1.28 1.04 1.07 1.13 1.17
Mm.26687
1
KLA  ATP  ATP+KLA
 80978931 Unknown KLA .67 .63 .70 .83 1.66 1.43 1.54
ATP 1.20 1.24 1.22 1.26 1.80 .81 1.02
KLA/ATP .63 .56 .83 1.06 1.26 .70 1.34
Mm.27574
2
KLA  ATP  ATP+KLA
 112983655 Unknown KLA 1.35 1.16 .94 .85 .45 .33 .31
ATP .90 .86 1.17 1.09 1.18 1.21 .38
KLA/ATP 1.12 1.22 1.19 .91 .90 .83 .33
Mm.27768
7
KLA  ATP  ATP+KLA
 92091594 Unknown KLA 1.43 1.51 1.70 1.77 2.48 2.13 1.68
ATP 1.06 1.11 .87 1.02 1.16 1.16 1.34
KLA/ATP 1.54 1.39 1.11 1.41 1.32 1.27 1.15
Mm.27992
3
KLA  ATP  ATP+KLA
 56699422 Unknown KLA .96 .90 .93 .88 .86 .84 .91
ATP .97 1.02 1.03 .99 .91 .89 .90
KLA/ATP .90 .93 .93 .93 .90 .91 .81
Mm.29002
6
KLA  ATP  ATP+KLA
 146141141 Unknown KLA .86 .76 .74 .94 .70 .57 .57
ATP 1.05 .94 1.16 1.33 2.13 2.57 1.15
KLA/ATP .74 .84 1.09 1.07 1.49 2.42 1.05
Mm.29018
2
KLA  ATP  ATP+KLA
 51921284 Unknown KLA .80 .75 .79 .87 .86 .96 .92
ATP .93 .94 1.07 1.07 1.77 1.52 1.50
KLA/ATP .74 .71 .76 .87 1.61 1.64 1.53
Mm.30667
3
KLA  ATP  ATP+KLA
 94391054 Unknown KLA .63 .58 .62 .83 .80 1.04 .85
ATP 1.02 .86 1.23 .78 .49 .83 1.04
KLA/ATP .57 .58 .83 .59 .63 .68 .93
Mm.32801
KLA  ATP  ATP+KLA
 17941276 Unknown KLA 1.45 1.48 1.50 1.95 1.69 1.54 .94
ATP 1.04 .85 1.12 .69 .38 1.14 1.07
KLA/ATP 1.22 1.37 1.97 1.22 .87 1.15 1.24
Mm.33676
1
KLA  ATP  ATP+KLA
 158508708 Unknown KLA .76 .84 .75 .92 .80 .81 .64
ATP 1.11 1.02 .90 .91 .79 .85 .69
KLA/ATP .69 .80 .96 .83 .79 .82 .68
Mm.35894
6
KLA  ATP  ATP+KLA
 147907211 Unknown KLA .47 .50 .47 .51 .32 .36 .34
ATP 1.03 .98 .91 .66 .35 .55 .72
KLA/ATP .46 .47 .53 .48 .33 .41 .41
Mm.41274
5
KLA  ATP  ATP+KLA
 110681696 Unknown KLA .97 1.07 1.11 1.07 1.38 1.63 1.35
ATP 1.06 1.09 1.05 1.29 1.04 .50 .56
KLA/ATP 1.11 1.12 1.04 1.11 .92 .83 .74
Mm.43967
5
KLA  ATP  ATP+KLA
 133778954 Unknown KLA 1.76 1.74 1.70 1.72 1.75 2.14 3.19
ATP 1.00 1.01 1.18 1.28 1.25 1.48 1.84
KLA/ATP 1.67 1.64 1.70 1.79 1.63 2.04 3.36
Mm.43967
5
KLA  ATP  ATP+KLA
 149275074 Unknown KLA 2.17 2.23 2.26 2.58 2.26 2.10 1.43
ATP .96 .91 1.12 .90 .70 1.10 1.47
KLA/ATP 1.96 2.10 1.92 1.51 1.12 1.35 1.99
Mm.44165
1
KLA  ATP  ATP+KLA
 160333403 Unknown KLA 5.45 5.27 5.02 6.34 6.63 10.05 8.10
ATP .91 .84 .96 .75 .78 3.91 6.03
KLA/ATP 4.29 4.38 4.50 3.55 4.22 7.22 17.63
Mm.46002
4
KLA  ATP  ATP+KLA
 38348245 Unknown KLA 1.22 1.25 1.25 1.19 1.22 1.47 1.14
ATP 1.03 .94 1.01 1.01 2.67 2.31 1.37
KLA/ATP 1.35 1.19 1.27 1.22 1.99 1.83 1.45
Mm.47429
8
KLA  ATP  ATP+KLA
 30794415 Unknown KLA 1.19 1.08 1.03 1.09 .87 .84 1.12
ATP .85 .86 1.35 1.12 1.05 1.28 1.21
KLA/ATP .94 1.02 1.67 1.25 1.37 1.16 1.07
Mm.57199
KLA  ATP  ATP+KLA
 124256486 Unknown KLA .97 .97 .95 1.05 .96 .94 1.02
ATP .95 1.00 .96 .94 .97 1.05 .95
KLA/ATP .94 1.00 .86 1.02 .97 .96 .99
Mm.80682
KLA  ATP  ATP+KLA
 94369627 Unknown KLA .96 1.00 .97 .97 1.07 1.05 .99
ATP .97 1.02 .98 1.01 1.01 1.06 .96
KLA/ATP 1.00 .93 1.02 1.08 .98 .95 .97
Mm.81698
KLA  ATP  ATP+KLA
 158937287 Unknown KLA .95 1.02 1.04 .98 1.01 1.04 1.08
ATP 1.00 1.03 .97 1.00 1.03 .98 .96
KLA/ATP 1.07 1.00 .94 .98 1.03 1.05 .97
Nedd4
KLA  ATP  ATP+KLA
 NM_010890 neural precursor cell expressed, developmentally down-regulated gene 4 (Nedd4), mRNA [NM_010890] KLA 1.00 1.04 1.03 1.02 .85 .94 .95
ATP 1.04 1.05 1.03 1.06 1.01 .89 .80
KLA/ATP 1.04 .99 1.02 1.05 .99 .90 .82
Nedd4l
KLA  ATP  ATP+KLA
 NM_031881 neural precursor cell expressed, developmentally down-regulated gene 4-like (Nedd4l), transcript variant 2, mRNA [NM_031881] KLA 1.42 1.30 1.43 .83 .53 .47 .54
ATP 1.01 1.24 1.06 2.34 8.62 2.38 1.38
KLA/ATP 1.65 1.59 1.17 1.66 3.43 2.75 1.38
Ntrk1
KLA  ATP  ATP+KLA
 NM_001033124 neurotrophic tyrosine kinase, receptor, type 1 (Ntrk1), mRNA [NM_001033124] KLA .95 .96 1.03 1.03 .95 1.01 1.02
ATP 1.04 .98 .98 1.07 .99 1.01 1.02
KLA/ATP .97 1.03 1.10 1.02 1.05 1.00 .97
Pard3
KLA  ATP  ATP+KLA
 AK076429 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4832405A21 product:par-3 (partitioning defective 3) homolog (C. elegans), full insert sequence. [AK076429] KLA .96 .96 1.03 .96 1.03 .99 1.19
ATP .97 .92 1.09 .99 1.00 1.03 .94
KLA/ATP .97 1.01 .97 1.05 .98 .92 1.04
Pard3
KLA  ATP  ATP+KLA
 NM_001013580 par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 2, mRNA [NM_001013580] KLA 1.02 .99 1.03 .97 1.00 .97 1.04
ATP .93 1.02 .98 .95 1.02 1.02 .98
KLA/ATP 1.04 .98 1.01 .99 .96 .91 .95
Pard3
KLA  ATP  ATP+KLA
 NM_001013581 par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 1, mRNA [NM_001013581] KLA .99 1.06 1.02 1.02 1.00 .98 .95
ATP .91 1.05 1.06 .99 1.04 .89 .99
KLA/ATP .98 .97 1.09 .97 1.01 .98 1.00
Pard3
KLA  ATP  ATP+KLA
 NM_001122850 par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 4, mRNA [NM_001122850] KLA 1.01 .95 1.00 1.01 1.07 .91 .99
ATP 1.00 1.01 .98 .94 1.04 .98 1.00
KLA/ATP .99 .99 1.04 1.04 1.04 1.01 1.03
Pard3
KLA  ATP  ATP+KLA
 NM_033620 par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 3, mRNA [NM_033620] KLA .92 .93 .97 .96 1.00 .99 1.02
ATP 1.08 1.03 .93 .92 .99 .97 1.00
KLA/ATP .99 1.03 1.02 1.05 .96 1.06 1.03
Pard6a
KLA  ATP  ATP+KLA
 NM_001047436 par-6 (partitioning defective 6,) homolog alpha (C. elegans) (Pard6a), transcript variant 3, mRNA [NM_001047436] KLA .85 .86 .99 1.14 1.22 1.22 1.02
ATP 1.17 1.16 1.11 1.14 .92 1.12 1.29
KLA/ATP .84 .88 1.14 1.20 1.22 1.32 1.26
Pard6b
KLA  ATP  ATP+KLA
 BC025147 par-6 (partitioning defective 6) homolog beta (C. elegans), mRNA (cDNA clone MGC:35871 IMAGE:2655658), complete cds [BC025147] KLA .97 .97 .91 .92 .92 .95 .97
ATP .97 .99 .99 .99 1.10 1.02 1.10
KLA/ATP .99 .97 .96 .95 1.10 1.11 1.13
Pard6b
KLA  ATP  ATP+KLA
 NM_021409 par-6 (partitioning defective 6) homolog beta (C. elegans) (Pard6b), mRNA [NM_021409] KLA .96 1.04 .96 1.03 .98 1.07 1.04
ATP 1.00 .92 1.02 1.01 .97 1.01 .98
KLA/ATP 1.02 .92 1.03 1.02 1.01 .97 1.01
Pard6g
KLA  ATP  ATP+KLA
 AK019835 adult male testis cDNA, RIKEN full-length enriched library, clone:4930590G08 product:unclassifiable, full insert sequence. [AK019835] KLA .95 .95 .84 .86 .78 .80 .76
ATP 1.01 .94 1.00 .88 .84 .89 .73
KLA/ATP .90 .87 .87 .81 .82 .73 .73
Pard6g
KLA  ATP  ATP+KLA
 NM_053117 par-6 partitioning defective 6 homolog gamma (C. elegans) (Pard6g), mRNA [NM_053117] KLA .92 .83 .73 .69 .56 .68 .57
ATP .98 .89 .92 .83 .69 .80 .56
KLA/ATP .86 .81 .72 .73 .66 .70 .53
Pdcd6ip
KLA  ATP  ATP+KLA
 AK035750 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630001B13 product:inferred: programmed cell death 6 interacting protein, full insert sequence [AK035750] KLA .98 .90 .97 .88 .85 .66 .64
ATP 1.23 1.26 .97 1.03 .75 .25 .25
KLA/ATP 1.01 1.08 .82 .70 .56 .28 .14
Pdcd6ip
KLA  ATP  ATP+KLA
 NM_011052 programmed cell death 6 interacting protein (Pdcd6ip), mRNA [NM_011052] KLA 1.34 1.28 1.42 1.33 1.46 1.29 1.31
ATP 1.16 1.40 1.01 1.55 1.12 1.06 1.33
KLA/ATP 1.43 1.66 1.03 1.72 .85 1.20 1.53
Pdgfra
KLA  ATP  ATP+KLA
 NM_011058 platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] KLA 1.02 1.05 1.02 1.01 1.03 1.03 1.01
ATP 1.01 1.02 1.03 1.04 1.00 1.01 1.01
KLA/ATP 1.01 1.01 .99 1.03 1.02 1.03 1.01
Pip5k1a
KLA  ATP  ATP+KLA
 NM_008847 phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha (Pip5k1a), mRNA [NM_008847] KLA 1.99 1.84 1.66 1.49 1.49 1.37 1.57
ATP 1.05 1.06 .89 1.54 4.20 2.72 1.58
KLA/ATP 1.95 1.90 1.55 1.60 3.26 2.64 2.25
Pip5k1b
KLA  ATP  ATP+KLA
 NM_008846 phosphatidylinositol-4-phosphate 5-kinase, type 1 beta (Pip5k1b), mRNA [NM_008846] KLA 1.24 1.35 1.11 .92 .57 .72 .86
ATP .86 1.00 .96 1.15 .85 .74 .89
KLA/ATP 1.20 1.22 .97 1.00 .78 .76 1.06
Pip5k1c
KLA  ATP  ATP+KLA
 BC094665 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma, mRNA (cDNA clone MGC:102155 IMAGE:30356181), complete cds [BC094665] KLA .82 .90 .90 .70 .96 .86 1.21
ATP 1.19 1.45 .92 1.64 1.17 .83 1.33
KLA/ATP .97 1.21 .66 1.20 .91 .92 1.69
Pip5k1c
KLA  ATP  ATP+KLA
 NM_008844 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma (Pip5k1c), mRNA [NM_008844] KLA 1.40 1.36 1.38 1.39 1.30 1.30 1.27
ATP 1.01 1.16 1.12 1.46 1.38 1.35 1.21
KLA/ATP 1.39 1.44 1.44 1.64 1.41 1.45 1.53
Pip5kl1
KLA  ATP  ATP+KLA
 NM_198191 phosphatidylinositol-4-phosphate 5-kinase-like 1 (Pip5kl1), mRNA [NM_198191] KLA .99 .97 .96 1.03 1.01 1.04 1.02
ATP .98 .92 .97 1.63 2.17 1.17 .99
KLA/ATP 1.05 1.00 1.10 1.19 1.24 1.27 1.06
Pld1
KLA  ATP  ATP+KLA
 NM_008875 phospholipase D1 (Pld1), mRNA [NM_008875] KLA .71 .73 .67 .73 .88 .96 1.25
ATP .99 .88 .73 .68 .45 1.23 1.12
KLA/ATP .70 .67 .58 .59 .48 .91 1.48
Pld2
KLA  ATP  ATP+KLA
 NM_008876 phospholipase D2 (Pld2), mRNA [NM_008876] KLA .51 .54 .48 .51 .73 .79 1.02
ATP 1.06 1.10 .88 1.03 1.04 1.29 1.00
KLA/ATP .63 .52 .40 .57 .65 1.03 1.35
Pml
KLA  ATP  ATP+KLA
 NM_008884 promyelocytic leukemia (Pml), transcript variant 1, mRNA [NM_008884] KLA 5.73 6.01 7.28 6.76 5.85 5.36 2.28
ATP 1.07 1.10 .92 .89 .97 3.78 2.67
KLA/ATP 6.48 6.51 6.81 8.78 6.61 7.57 6.55
Prkci
KLA  ATP  ATP+KLA
 NM_008857 protein kinase C, iota (Prkci), mRNA [NM_008857] KLA .92 .84 .75 .59 .50 .66 .90
ATP 1.06 1.20 1.15 1.10 1.14 1.04 1.00
KLA/ATP .83 .92 .75 .78 .99 1.06 .80
Prkcz
KLA  ATP  ATP+KLA
 NM_008860 protein kinase C, zeta (Prkcz), transcript variant 1, mRNA [NM_008860] KLA .92 .90 1.00 .99 1.07 1.05 1.12
ATP 1.01 .95 .94 .93 1.04 1.04 .95
KLA/ATP .95 .94 .95 .94 .99 1.02 .98
Psd
KLA  ATP  ATP+KLA
 AK220438 premature mRNA for mKIAA2011 protein [AK220438] KLA 1.04 1.00 .99 1.01 1.01 .95 .95
ATP .99 1.06 1.07 1.00 .96 1.09 .98
KLA/ATP 1.09 .97 1.04 1.05 .96 1.03 1.11
Psd
KLA  ATP  ATP+KLA
 NM_028627 pleckstrin and Sec7 domain containing (Psd), mRNA [NM_028627] KLA 1.29 1.26 1.32 1.23 1.29 1.19 1.13
ATP 1.03 1.01 1.16 1.30 1.36 1.22 1.19
KLA/ATP 1.31 1.39 1.51 1.52 1.48 1.22 1.28
Psd2
KLA  ATP  ATP+KLA
 NM_028707 pleckstrin and Sec7 domain containing 2 (Psd2), mRNA [NM_028707] KLA .96 .89 1.01 .89 1.10 1.16 1.14
ATP 1.05 .94 1.13 1.04 .81 .66 .46
KLA/ATP .87 .91 1.01 .94 .84 .62 .53
Psd3
KLA  ATP  ATP+KLA
 NM_177698 pleckstrin and Sec7 domain containing 3 (Psd3), transcript variant 2, mRNA [NM_177698] KLA 1.74 1.60 1.48 .94 .91 .79 .50
ATP 1.09 .99 1.16 .99 .98 .45 .51
KLA/ATP 1.69 1.72 1.62 .94 .60 .23 .29
Psd4
KLA  ATP  ATP+KLA
 NM_177611 pleckstrin and Sec7 domain containing 4 (Psd4), mRNA [NM_177611] KLA 1.62 1.76 2.09 2.14 2.57 2.02 1.08
ATP 1.11 1.21 1.05 1.14 1.34 1.30 1.83
KLA/ATP 1.94 2.04 1.64 1.85 1.16 1.07 2.88
Rab11a
KLA  ATP  ATP+KLA
 NM_017382 RAB11a, member RAS oncogene family (Rab11a), mRNA [NM_017382] KLA .96 .92 .94 .94 1.01 1.05 1.00
ATP 1.04 1.08 1.09 1.15 .88 .73 .87
KLA/ATP .99 .98 .96 1.03 .84 .74 .97
Rab11b
KLA  ATP  ATP+KLA
 NM_008997 RAB11B, member RAS oncogene family (Rab11b), mRNA [NM_008997] KLA 1.00 .99 1.02 .93 1.03 1.00 .95
ATP 1.10 1.20 .97 1.33 1.13 1.13 .90
KLA/ATP 1.12 1.11 .87 1.26 1.00 1.14 1.12
Rab11fip
1
KLA  ATP  ATP+KLA
 NM_001080813 RAB11 family interacting protein 1 (class I) (Rab11fip1), mRNA [NM_001080813] KLA 9.47 8.48 8.02 8.87 10.49 4.04 2.63
ATP 1.04 1.02 1.76 5.51 20.27 25.38 2.73
KLA/ATP 9.22 9.76 13.57 15.57 21.68 26.71 18.07
Rab11fip
2
KLA  ATP  ATP+KLA
 NM_001033172 RAB11 family interacting protein 2 (class I) (Rab11fip2), mRNA [NM_001033172] KLA .99 .95 .97 .96 .88 .92 1.00
ATP 1.03 1.06 .98 .87 .71 .84 1.03
KLA/ATP .98 .98 .91 .82 .78 .83 .88
Rab11fip
3
KLA  ATP  ATP+KLA
 XM_484616 gb|PREDICTED: Mus musculus RAB11 family interacting protein 3 (class II), transcript variant 1 (Rab11fip3), mRNA [XM_484616] KLA .70 .69 .67 .66 .68 .68 .81
ATP .93 .83 .80 .64 .43 .80 .98
KLA/ATP .61 .62 .65 .50 .47 .65 .80
Rab11fip
4
KLA  ATP  ATP+KLA
 AK147344 adult male brain UNDEFINED_CELL_LINE cDNA, RIKEN full-length enriched library, clone:M5C1016L22 product:Hypothetical EF-hand containing protein, full insert sequence [AK147344] KLA 1.06 1.00 1.05 .98 .96 .99 1.00
ATP .96 1.07 .96 1.06 1.10 1.05 1.02
KLA/ATP 1.09 1.04 .82 .96 .99 .97 .98
Rab11fip
4
KLA  ATP  ATP+KLA
 NM_175543 RAB11 family interacting protein 4 (class II) (Rab11fip4), mRNA [NM_175543] KLA 1.09 .99 1.05 .93 .97 .94 .85
ATP .96 .97 1.04 .92 .99 1.10 1.07
KLA/ATP 1.06 1.08 .96 .97 .93 .95 1.01
Rab11fip
5
KLA  ATP  ATP+KLA
 NM_001003955 RAB11 family interacting protein 5 (class I) (Rab11fip5), transcript variant 1, mRNA [NM_001003955] KLA .58 .60 .90 1.29 1.79 1.38 .63
ATP 1.05 1.07 .94 .82 .78 .73 1.17
KLA/ATP .60 .58 .61 .68 .91 1.08 1.15
Rab22a
KLA  ATP  ATP+KLA
 AK147619 adult male brain UNDEFINED_CELL_LINE cDNA, RIKEN full-length enriched library, clone:M5C1093C21 product:RAB22A, member RAS oncogene family, full insert sequence [AK147619] KLA 1.23 1.07 1.02 .96 .88 .74 .59
ATP .97 .88 1.07 .95 1.76 .83 .37
KLA/ATP 1.10 1.01 1.16 1.33 3.74 1.60 .55
Rab22a
KLA  ATP  ATP+KLA
 NM_024436 RAB22A, member RAS oncogene family (Rab22a), mRNA [NM_024436] KLA 2.76 2.79 3.04 3.28 3.18 3.03 1.78
ATP 1.11 1.26 1.15 1.52 1.79 2.39 2.57
KLA/ATP 3.00 3.12 2.78 3.75 2.93 2.94 5.26
Rab31
KLA  ATP  ATP+KLA
 NM_133685 RAB31, member RAS oncogene family (Rab31), mRNA [NM_133685] KLA .56 .59 .69 .90 1.49 1.64 .91
ATP .95 .82 .37 .31 .36 .54 .83
KLA/ATP .62 .53 .30 .35 .40 .60 .93
Rab4a
KLA  ATP  ATP+KLA
 D86563 mRNA for rab 4, complete cds. [D86563] KLA .44 .40 .38 .35 .33 .44 .83
ATP 1.27 1.29 .91 1.53 3.54 1.65 1.40
KLA/ATP .51 .46 .32 .54 2.27 2.38 .79
Rab5a
KLA  ATP  ATP+KLA
 AK036011 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630027A13 product:hypothetical protein, full insert sequence. [AK036011] KLA .98 1.01 .98 .93 1.04 .95 1.02
ATP 1.01 1.02 1.03 .96 1.08 1.04 1.08
KLA/ATP 1.06 1.02 1.02 .92 .99 1.01 1.08
Rab5a
KLA  ATP  ATP+KLA
 NM_025887 RAB5A, member RAS oncogene family (Rab5a), mRNA [NM_025887] KLA 1.88 1.84 2.12 2.01 1.68 1.40 1.18
ATP 1.00 .95 .93 .81 1.10 1.57 1.09
KLA/ATP 1.87 1.86 1.87 1.72 1.71 1.63 1.47
Rab5b
KLA  ATP  ATP+KLA
 AK144551 adult male intestinal mucosa cDNA, RIKEN full-length enriched library, clone:G630095F06 product:RAB5B, member RAS oncogene family, full insert sequence. [AK144551] KLA .84 .93 1.00 .83 1.07 .95 1.19
ATP 1.11 1.01 .75 .84 .97 .93 .88
KLA/ATP .95 .87 .64 .88 .98 .99 .93
Rab5b
KLA  ATP  ATP+KLA
 NM_011229 RAB5B, member RAS oncogene family (Rab5b), mRNA [NM_011229] KLA 1.07 1.13 1.29 1.05 1.14 1.06 1.16
ATP 1.15 1.16 .78 .83 .93 .92 1.15
KLA/ATP 1.22 1.15 .77 .86 .87 .93 1.30
Rab5b
KLA  ATP  ATP+KLA
 NM_177411 RAB5B, member RAS oncogene family (Rab5b), mRNA [NM_177411] KLA 1.38 1.33 1.46 1.18 1.23 1.31 1.30
ATP 1.07 1.32 .83 1.08 .71 1.02 1.34
KLA/ATP 1.57 1.58 .95 1.38 .76 1.04 1.55
Rab5c
KLA  ATP  ATP+KLA
 NM_024456 RAB5C, member RAS oncogene family (Rab5c), mRNA [NM_024456] KLA .96 1.26 1.45 1.13 1.14 1.50 1.17
ATP .95 1.30 1.32 1.01 .98 1.03 1.04
KLA/ATP 1.11 1.37 1.61 1.15 1.00 1.18 1.52
Rab7
KLA  ATP  ATP+KLA
 BI654107 gb|603280186F1 NCI_CGAP_Mam4 Mus musculus cDNA clone IMAGE:5310477 5, mRNA sequence [BI654107] KLA 1.08 1.15 1.33 1.10 1.13 1.26 1.24
ATP .99 1.11 1.08 1.39 1.49 1.69 2.44
KLA/ATP 1.19 1.17 1.12 1.51 1.30 1.77 2.20
Rab7
KLA  ATP  ATP+KLA
 DV064670 gb|NEONATAL_23_D05.x1 FH NEONATAL Mus musculus cDNA clone NEONATAL_23_D05 similar to RAB7 member RAS oncogene family, mRNA sequence [DV064670] KLA 1.01 1.03 1.05 .90 .94 .97 1.09
ATP 1.05 1.16 1.00 1.26 1.36 1.36 1.97
KLA/ATP 1.16 1.08 .77 1.23 1.12 1.41 1.50
Rabep1
KLA  ATP  ATP+KLA
 NM_019400 rabaptin, RAB GTPase binding effector protein 1 (Rabep1), mRNA [NM_019400] KLA 1.05 1.06 1.22 1.14 1.27 1.15 1.31
ATP 1.00 .96 1.10 1.16 2.71 1.52 1.22
KLA/ATP 1.05 1.07 1.20 .97 1.79 1.45 1.65
Ret
KLA  ATP  ATP+KLA
 NM_009050 ret proto-oncogene (Ret), transcript variant 2, mRNA [NM_009050] KLA 1.00 1.00 1.04 1.02 1.03 1.01 1.02
ATP 1.02 .98 1.01 1.00 .99 1.01 1.01
KLA/ATP 1.01 .97 1.02 1.01 1.00 1.00 .98
Rhoa
KLA  ATP  ATP+KLA
 NM_016802 ras homolog gene family, member A (Rhoa), mRNA [NM_016802] KLA .93 1.00 1.07 .97 1.08 1.06 1.02
ATP .93 .88 .49 .61 .63 .78 1.05
KLA/ATP .94 .92 .59 .63 .61 .78 1.12
Rufy1
KLA  ATP  ATP+KLA
 NM_172557 RUN and FYVE domain containing 1 (Rufy1), mRNA [NM_172557] KLA .67 .68 .70 .69 .83 .94 .87
ATP 1.01 1.03 1.14 1.12 .72 .58 1.05
KLA/ATP .68 .73 .70 .77 .67 .69 1.01
Sh3gl1
KLA  ATP  ATP+KLA
 NM_013664 SH3-domain GRB2-like 1 (Sh3gl1), mRNA [NM_013664] KLA .85 .78 1.04 1.33 1.89 1.15 .63
ATP .98 1.06 .86 .77 1.59 1.09 1.16
KLA/ATP .84 .83 .79 1.00 1.96 1.35 .96
Sh3gl2
KLA  ATP  ATP+KLA
 AK035210 adult male urinary bladder cDNA, RIKEN full-length enriched library, clone:9530001L19 product:SH3 DOMAIN PROTEIN 2A homolog [Mus musculus], full insert sequence. [AK035210] KLA 1.02 1.00 1.12 .99 1.01 1.02 .98
ATP .97 1.01 1.04 .94 .91 1.01 .96
KLA/ATP 1.00 1.02 1.05 1.00 1.00 .99 1.08
Sh3gl3
KLA  ATP  ATP+KLA
 NM_017400 SH3-domain GRB2-like 3 (Sh3gl3), mRNA [NM_017400] KLA 1.00 .98 1.11 .98 1.04 1.02 1.08
ATP 1.05 .92 1.08 1.14 1.04 1.09 1.24
KLA/ATP 1.02 1.02 1.07 1.09 1.08 1.06 1.04
Sh3glb1
KLA  ATP  ATP+KLA
 AK086477 15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930031E24 product:SH3-domain GRB2-like B1 (endophilin), full insert sequence [AK086477] KLA 2.16 2.26 2.33 2.38 2.10 1.45 .83
ATP 1.00 .99 1.09 1.06 1.09 .73 .44
KLA/ATP 2.09 2.43 2.32 2.09 1.69 .92 .34
Sh3glb1
KLA  ATP  ATP+KLA
 NM_019464 SH3-domain GRB2-like B1 (endophilin) (Sh3glb1), mRNA [NM_019464] KLA 2.18 2.51 2.92 2.62 2.95 2.27 1.57
ATP 1.12 1.32 1.02 1.52 1.52 1.48 1.11
KLA/ATP 2.52 2.64 2.03 3.33 2.60 2.20 1.45
Sh3glb2
KLA  ATP  ATP+KLA
 NM_139302 SH3-domain GRB2-like endophilin B2 (Sh3glb2), mRNA [NM_139302] KLA .84 .83 .85 .79 .78 .83 1.02
ATP .98 1.05 1.01 1.18 .89 .57 1.11
KLA/ATP .88 .86 .77 .92 .71 .63 .98
Sh3kbp1
KLA  ATP  ATP+KLA
 NM_021389 SH3-domain kinase binding protein 1 (Sh3kbp1), mRNA [NM_021389] KLA 1.97 1.95 1.97 1.95 2.28 2.27 1.55
ATP 1.00 1.09 .97 1.23 .96 .70 1.38
KLA/ATP 1.89 2.19 1.85 2.27 1.39 1.10 1.55
Smad2
KLA  ATP  ATP+KLA
 NM_010754 MAD homolog 2 (Drosophila) (Smad2), mRNA [NM_010754] KLA 1.05 1.08 1.04 1.17 1.40 1.43 1.59
ATP 1.01 1.02 1.16 1.14 1.15 1.32 1.34
KLA/ATP 1.00 .99 .97 1.09 1.40 1.14 1.40
Smad3
KLA  ATP  ATP+KLA
 NM_016769 MAD homolog 3 (Drosophila) (Smad3), mRNA [NM_016769] KLA .64 .60 .57 .64 .70 1.25 1.52
ATP 1.02 1.02 .84 1.21 2.42 .90 1.19
KLA/ATP .64 .60 .65 .66 1.29 1.26 2.26
Smad6
KLA  ATP  ATP+KLA
 NM_008542 MAD homolog 6 (Drosophila) (Smad6), mRNA [NM_008542] KLA .71 .74 .47 .60 .98 2.87 4.17
ATP 1.07 1.07 .80 1.15 2.35 1.34 3.16
KLA/ATP .67 .76 .52 .63 .81 1.31 4.48
Smad7
KLA  ATP  ATP+KLA
 NM_001042660 MAD homolog 7 (Drosophila) (Smad7), mRNA [NM_001042660] KLA .58 .57 .41 .72 .72 1.04 .97
ATP 1.14 1.16 1.84 4.55 2.55 1.97 1.44
KLA/ATP .64 .58 .65 2.41 2.10 1.98 2.69
Smap1
KLA  ATP  ATP+KLA
 AK006817 adult male testis cDNA, RIKEN full-length enriched library, clone:1700056O10 product:similar to STROMAL MEMBRANE-ASSOCIATED PROTEIN SMAP1A [Homo sapiens], full insert sequence. [AK006817] KLA 1.18 1.31 1.35 1.34 1.65 1.79 1.56
ATP 1.00 1.01 1.11 1.25 1.20 1.39 1.16
KLA/ATP 1.24 1.26 1.27 1.41 1.27 1.39 1.89
Smap1
KLA  ATP  ATP+KLA
 NM_028534 stromal membrane-associated protein 1 (Smap1), mRNA [NM_028534] KLA 1.04 1.14 1.03 1.23 1.58 1.67 1.45
ATP .97 .96 1.07 1.19 1.14 1.53 1.19
KLA/ATP 1.02 1.05 1.10 1.26 1.16 1.50 2.15
Smap2
KLA  ATP  ATP+KLA
 NM_133716 stromal membrane-associated GTPase-activating protein 2 (Smap2), mRNA [NM_133716] KLA 1.67 1.59 1.70 1.48 1.24 1.20 .93
ATP 1.06 1.00 .87 .98 .88 .99 1.38
KLA/ATP 1.65 1.62 1.47 1.52 1.23 1.25 1.84
Smurf1
KLA  ATP  ATP+KLA
 NM_001038627 SMAD specific E3 ubiquitin protein ligase 1 (Smurf1), transcript variant 1, mRNA [NM_001038627] KLA 1.94 1.84 1.87 1.68 1.85 2.06 2.12
ATP 1.04 1.10 1.05 1.05 1.43 2.14 2.38
KLA/ATP 1.95 2.05 1.81 1.79 1.55 2.17 3.75
Smurf2
KLA  ATP  ATP+KLA
 NM_025481 SMAD specific E3 ubiquitin protein ligase 2 (Smurf2), mRNA [NM_025481] KLA .66 .66 .71 .75 1.11 1.14 1.16
ATP 1.03 1.10 1.22 .90 1.15 1.09 1.19
KLA/ATP .71 .72 .76 .65 1.04 .96 1.30
Snf8
KLA  ATP  ATP+KLA
 BC030490 SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae), mRNA (cDNA clone IMAGE:5372918) [BC030490] KLA 1.28 1.38 1.40 1.36 1.66 1.57 1.54
ATP .88 .63 .33 .57 .96 1.39 .94
KLA/ATP 1.17 .78 .51 .81 .93 1.48 1.45
Snf8
KLA  ATP  ATP+KLA
 NM_033568 SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae) (Snf8), mRNA [NM_033568] KLA 1.04 1.10 1.11 1.06 1.16 1.24 1.30
ATP .92 .82 .67 .58 .57 .96 1.38
KLA/ATP 1.00 .96 .87 .74 .76 1.02 1.60
Src
KLA  ATP  ATP+KLA
 NM_009271 Rous sarcoma oncogene (Src), transcript variant 1, mRNA [NM_009271] KLA 6.99 7.23 7.54 5.99 5.34 3.39 3.00
ATP 1.02 1.06 1.06 2.08 4.41 5.03 3.97
KLA/ATP 7.44 7.51 5.48 6.24 4.86 5.86 7.90
Stam
KLA  ATP  ATP+KLA
 NM_011484 signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 (Stam), mRNA [NM_011484] KLA 1.04 .95 1.11 1.01 .74 .84 1.27
ATP 1.08 1.16 1.41 1.31 2.25 2.07 1.27
KLA/ATP 1.07 1.13 1.25 1.21 1.44 1.59 1.36
Stam2
KLA  ATP  ATP+KLA
 NM_019667 signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 (Stam2), mRNA [NM_019667] KLA 1.23 1.18 1.21 1.17 1.52 1.73 2.04
ATP 1.11 1.18 1.16 1.87 3.04 2.11 3.01
KLA/ATP 1.23 1.38 1.15 2.05 2.81 2.66 6.00
Stambp
KLA  ATP  ATP+KLA
 NM_024239 Stam binding protein (Stambp), mRNA [NM_024239] KLA 1.42 1.49 1.47 1.87 1.62 1.66 .99
ATP .87 .79 1.12 .73 .42 1.03 1.02
KLA/ATP 1.20 1.34 1.76 1.24 .94 1.27 1.26
Tfrc
KLA  ATP  ATP+KLA
 NM_011638 transferrin receptor (Tfrc), mRNA [NM_011638] KLA .77 .79 .86 .63 .45 .25 .31
ATP 1.07 1.11 1.09 .89 .75 .45 .17
KLA/ATP .89 .85 .77 .66 .40 .24 .09
Tgfb1
KLA  ATP  ATP+KLA
 NM_011577 transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] KLA .87 .89 .90 .70 .83 .77 1.12
ATP 1.20 1.41 .80 1.49 1.11 .93 .99
KLA/ATP 1.10 1.20 .53 1.05 .66 .85 .90
Tgfb2
KLA  ATP  ATP+KLA
 NM_009367 transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] KLA 1.01 .91 .98 .98 .92 1.19 .96
ATP .99 1.03 1.00 1.02 .99 1.07 .93
KLA/ATP 1.02 .99 1.03 .98 1.04 1.06 .96
Tgfb3
KLA  ATP  ATP+KLA
 NM_009368 transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] KLA .67 .64 .58 .56 .49 .52 .61
ATP .90 .92 1.33 1.08 .78 .65 .74
KLA/ATP .58 .60 .74 .61 .76 1.36 1.51
Tgfbr1
KLA  ATP  ATP+KLA
 NM_009370 transforming growth factor, beta receptor I (Tgfbr1), mRNA [NM_009370] KLA .73 .74 .59 .54 .52 .64 .84
ATP .99 1.12 .99 1.16 1.22 .84 .93
KLA/ATP .75 .78 .58 .64 .62 .59 .77
Tgfbr2
KLA  ATP  ATP+KLA
 AK090393 10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] KLA .98 .89 1.00 .96 .94 1.00 .92
ATP .99 .99 .90 .94 .93 .96 1.02
KLA/ATP .92 .96 .98 .98 .98 .95 1.01
Tgfbr2
KLA  ATP  ATP+KLA
 NM_009371 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] KLA .55 .50 .58 .50 .52 .55 .44
ATP .98 .75 .50 .32 .41 .29 .50
KLA/ATP .59 .45 .32 .23 .31 .27 .25
Tgfbr2
KLA  ATP  ATP+KLA
 NM_029575 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] KLA .95 .93 .99 .95 .88 1.02 .82
ATP .87 .93 .84 .84 .74 .72 1.00
KLA/ATP .89 .85 .83 .85 .76 .80 .79
Traf6
KLA  ATP  ATP+KLA
 NM_009424 Tnf receptor-associated factor 6 (Traf6), mRNA [NM_009424] KLA 1.19 1.28 1.34 1.20 1.23 1.23 1.28
ATP 1.06 1.12 .92 1.15 2.46 1.84 1.40
KLA/ATP 1.32 1.37 .89 1.16 1.45 1.49 1.46
Tsg101
KLA  ATP  ATP+KLA
 NM_021884 tumor susceptibility gene 101 (Tsg101), mRNA [NM_021884] KLA 1.10 1.10 1.11 .98 1.03 1.08 1.31
ATP 1.12 1.26 1.16 1.38 1.13 .81 1.02
KLA/ATP 1.18 1.22 .96 1.33 .97 .93 1.21
Usp8
KLA  ATP  ATP+KLA
 AK040791 adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530025I19 product:ubiquitin specific protease 8, full insert sequence. [AK040791] KLA 1.06 .89 .88 .93 1.00 .90 .98
ATP 1.22 1.19 1.04 .77 .99 .90 .93
KLA/ATP 1.08 1.29 1.08 .80 1.05 .95 .91
Usp8
KLA  ATP  ATP+KLA
 NM_019729 ubiquitin specific peptidase 8 (Usp8), mRNA [NM_019729] KLA 1.38 1.21 1.42 1.21 1.36 1.21 1.09
ATP 1.28 1.35 1.03 1.18 .80 .60 .86
KLA/ATP 1.38 1.54 1.09 1.41 .92 1.00 1.18
Vps24
KLA  ATP  ATP+KLA
 NM_025783 vacuolar protein sorting 24 (yeast) (Vps24), mRNA [NM_025783] KLA .90 .94 1.03 .95 1.03 1.12 1.10
ATP 1.03 1.06 1.12 1.24 1.08 .76 .96
KLA/ATP .92 .97 1.03 1.06 1.00 .81 .92
Vps25
KLA  ATP  ATP+KLA
 NM_026776 vacuolar protein sorting 25 (yeast) (Vps25), mRNA [NM_026776] KLA 1.06 1.09 1.29 1.21 1.30 1.20 1.33
ATP 1.25 1.30 1.10 1.62 .98 .42 .98
KLA/ATP 1.41 1.42 1.12 1.74 1.05 .78 1.03
Vps28
KLA  ATP  ATP+KLA
 NM_025842 vacuolar protein sorting 28 (yeast) (Vps28), mRNA [NM_025842] KLA .95 .95 .94 .95 .93 .95 .91
ATP .94 .97 1.01 .99 .88 .81 .85
KLA/ATP .95 .94 1.01 .97 .94 .83 .81
Vps36
KLA  ATP  ATP+KLA
 NM_027338 vacuolar protein sorting 36 (yeast) (Vps36), mRNA [NM_027338] KLA 1.03 1.10 .88 1.04 .85 .83 1.03
ATP .92 .92 1.08 1.05 .90 .92 .94
KLA/ATP .97 1.14 1.39 1.19 1.06 .85 .79
Vps37a
KLA  ATP  ATP+KLA
 NM_033560 vacuolar protein sorting 37A (yeast) (Vps37a), mRNA [NM_033560] KLA 1.99 1.82 1.79 1.68 1.44 1.23 1.40
ATP .99 1.08 1.07 1.12 1.62 1.89 1.35
KLA/ATP 1.87 1.94 1.87 1.79 1.47 1.39 1.62
Vps37b
KLA  ATP  ATP+KLA
 NM_177876 vacuolar protein sorting 37B (yeast) (Vps37b), mRNA [NM_177876] KLA 1.70 1.88 1.59 1.25 1.60 2.21 1.57
ATP .85 .87 .71 1.74 3.86 2.08 2.25
KLA/ATP 1.80 1.74 1.13 1.76 3.88 3.02 3.94
Vps37c
KLA  ATP  ATP+KLA
 NM_181403 vacuolar protein sorting 37C (yeast) (Vps37c), mRNA [NM_181403] KLA 2.09 2.32 2.48 2.06 2.36 1.95 1.55
ATP 1.04 1.16 1.15 1.64 2.31 2.83 1.41
KLA/ATP 2.49 2.49 2.07 2.19 2.17 2.98 2.91
Vps37d
KLA  ATP  ATP+KLA
 NM_177574 vacuolar protein sorting 37D (yeast) (Vps37d), mRNA [NM_177574] KLA .94 .94 .78 .97 .82 .88 .86
ATP 1.02 .94 .87 .83 .79 1.02 .87
KLA/ATP .90 .94 .87 .80 .78 1.00 .94
Vps45
KLA  ATP  ATP+KLA
 NM_013841 vacuolar protein sorting 45 (yeast) (Vps45), mRNA [NM_013841] KLA .84 .89 .91 .92 1.03 1.14 .90
ATP .97 1.03 1.01 1.00 .79 .91 .94
KLA/ATP .86 .92 .91 .85 .83 1.25 1.07
Vps4a
KLA  ATP  ATP+KLA
 NM_126165 vacuolar protein sorting 4a (yeast) (Vps4a), mRNA [NM_126165] KLA 1.12 1.13 1.22 1.14 1.31 1.16 1.29
ATP 1.20 1.18 1.05 1.27 1.05 1.06 1.11
KLA/ATP 1.35 1.34 1.07 1.39 1.12 1.11 1.28
Vps4b
KLA  ATP  ATP+KLA
 AK034641 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430017H18 product:vacuolar protein sorting 4b (yeast), full insert sequence [AK034641] KLA 1.01 1.04 .99 1.06 .89 .92 1.05
ATP 1.03 .97 .84 .84 .86 .86 .94
KLA/ATP 1.04 .99 .82 .83 .75 .86 .86
Vps4b
KLA  ATP  ATP+KLA
 NM_009190 vacuolar protein sorting 4b (yeast) (Vps4b), mRNA [NM_009190] KLA 1.00 1.02 1.08 .95 1.01 1.04 1.08
ATP 1.04 1.01 .77 .74 1.05 1.42 1.14
KLA/ATP 1.05 .96 .72 .72 .71 1.10 1.14
Vta1
KLA  ATP  ATP+KLA
 AK085518 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630036M24 product:unclassifiable, full insert sequence. [AK085518] KLA 1.05 1.02 .98 .95 .99 .96 1.04
ATP .93 .99 .91 .98 1.06 .96 .98
KLA/ATP .99 .94 .87 .95 1.01 .96 .98
Vta1
KLA  ATP  ATP+KLA
 NM_025418 Vps20-associated 1 homolog (S. cerevisiae) (Vta1), mRNA [NM_025418] KLA 1.84 1.90 2.01 2.20 1.88 1.67 1.38
ATP .99 .95 1.22 1.11 1.09 1.48 1.32
KLA/ATP 1.74 1.92 2.54 2.01 1.69 1.65 1.76
Wwp1
KLA  ATP  ATP+KLA
 NM_177327 WW domain containing E3 ubiquitin protein ligase 1 (Wwp1), mRNA [NM_177327] KLA .55 .52 .40 .36 .26 .24 .40
ATP 1.03 1.13 .87 .82 .51 .25 .68
KLA/ATP .54 .52 .35 .40 .29 .21 .31
Zfyve16
KLA  ATP  ATP+KLA
 NM_173392 zinc finger, FYVE domain containing 16 (Zfyve16), mRNA [NM_173392] KLA 1.04 1.03 1.02 1.05 .99 1.06 1.01
ATP 1.03 1.06 1.00 .76 .86 1.01 .98
KLA/ATP 1.00 1.04 .95 .78 .84 .98 1.10
Zfyve20
KLA  ATP  ATP+KLA
 NM_030081 zinc finger, FYVE domain containing 20 (Zfyve20), mRNA [NM_030081] KLA .74 .69 .73 .77 .89 .95 .95
ATP .83 .73 .64 .50 .88 1.01 1.08
KLA/ATP .64 .60 .61 .53 .87 1.10 .94
Zfyve9
KLA  ATP  ATP+KLA
 AK081320 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130005E21 product:unclassifiable, full insert sequence. [AK081320] KLA .99 .99 1.02 .96 1.06 .94 1.06
ATP 1.01 .97 .98 .97 1.06 1.00 1.03
KLA/ATP .97 1.00 .99 1.01 1.20 .97 .96
Zfyve9
KLA  ATP  ATP+KLA
 BC094578 cDNA clone IMAGE:6851752 [BC094578] KLA .94 .98 .89 .92 .88 .93 .87
ATP 1.00 1.10 1.04 .91 .93 1.00 .91
KLA/ATP .93 .93 .88 .92 .86 .86 .90